BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1-e48. [PMID: 29462280 DOI: 10.1093/cid/cix1085] [Cited by in Crossref: 718] [Cited by in F6Publishing: 613] [Article Influence: 239.3] [Reference Citation Analysis]
Number Citing Articles
1 Stephenson B, Lanzas C, Lenhart S, Ponce E, Bintz J, Dubberke ER, Day J. Comparing intervention strategies for reducing Clostridioides difficile transmission in acute healthcare settings: an agent-based modeling study. BMC Infect Dis 2020;20:799. [PMID: 33115427 DOI: 10.1186/s12879-020-05501-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mizusawa M, Carroll KC. Advances and required improvements in methods to diagnosing Clostridioides difficile infections in the healthcare setting. Expert Rev Mol Diagn 2021;21:311-21. [PMID: 33682564 DOI: 10.1080/14737159.2021.1900737] [Reference Citation Analysis]
3 Heidebrecht HJ, Weiss WJ, Pulse M, Lange A, Gisch K, Kliem H, Mann S, Pfaffl MW, Kulozik U, von Eichel-Streiber C. Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model. Toxins (Basel) 2019;11:E98. [PMID: 30736358 DOI: 10.3390/toxins11020098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Sousa Gerós A, Simmons A, Drakesmith H, Aulicino A, Frost JN. The battle for iron in enteric infections. Immunology 2020;161:186-99. [PMID: 32639029 DOI: 10.1111/imm.13236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Cappetto CM. Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis. Am J Health Syst Pharm 2021;78:1374-81. [PMID: 33851215 DOI: 10.1093/ajhp/zxab161] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Summers BB, Yates M, Cleveland KO, Gelfand MS, Usery J. Fidaxomicin Compared With Oral Vancomycin for the Treatment of Severe Clostridium difficile-Associated Diarrhea: A Retrospective Review. Hosp Pharm 2020;55:268-72. [PMID: 32742016 DOI: 10.1177/0018578719844165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Carlson TJ, Gonzales-Luna AJ. Utilizing antibiotics to prevent Clostridioides difficile infection: does exposure to a risk factor decrease risk? A systematic review. J Antimicrob Chemother 2020;75:2735-42. [PMID: 32696044 DOI: 10.1093/jac/dkaa251] [Reference Citation Analysis]
8 Sax H, Schreiber PW, Clack L, Ratz D, Saint S, Greene MT, Kuster SP. Preventing healthcare-associated infection in Switzerland: Results of a national survey. Infect Control Hosp Epidemiol 2020;41:597-600. [PMID: 32279671 DOI: 10.1017/ice.2019.351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cross SJ, Morton TH, Wolf J. Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children. J Pediatric Infect Dis Soc 2021;10:S46-51. [PMID: 34791397 DOI: 10.1093/jpids/piab078] [Reference Citation Analysis]
10 Rubio-Terrés C, Aguado JM, Almirante B, Cobo J, Grau S, Salavert M, González Antona Sánchez E, López Gutiérrez C, Rubio-Rodríguez D. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. Eur J Clin Microbiol Infect Dis 2019;38:1105-11. [PMID: 30989419 DOI: 10.1007/s10096-019-03503-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
11 Lomeli BK, Galbraith H, Schettler J, Saviolakis GA, El-Amin W, Osborn B, Ravel J, Hazleton K, Lozupone CA, Evans RJ, Bell SJ, Ochsner UA, Jarvis TC, Baqar S, Janjic N. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrob Agents Chemother 2019;64:e01395-19. [PMID: 31685472 DOI: 10.1128/AAC.01395-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Graves N, Mitchell BG, Otter JA, Kiernan M. The cost-effectiveness of temporary single-patient rooms to reduce risks of healthcare-associated infection. J Hosp Infect 2021;116:21-8. [PMID: 34246721 DOI: 10.1016/j.jhin.2021.07.003] [Reference Citation Analysis]
13 Dieterle MG, Putler R, Perry DA, Menon A, Abernathy-Close L, Perlman NS, Penkevich A, Standke A, Keidan M, Vendrov KC, Bergin IL, Young VB, Rao K. Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection. mBio 2020;11:e00180-20. [PMID: 32371595 DOI: 10.1128/mBio.00180-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Hamilton LA, Behal ML. Altering Routine Intensive Care Unit Practices to Support Commensalism. Nutr Clin Pract 2020;35:433-41. [PMID: 32189422 DOI: 10.1002/ncp.10484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Johnson TM, Howard AH, Miller MA, Allen LL, Huang M, Molina KC, Bajrovic V. Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients. Open Forum Infect Dis 2021;8:ofab294. [PMID: 34262988 DOI: 10.1093/ofid/ofab294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Thanissery R, Zeng D, Doyle RG, Theriot CM. A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile. Front Microbiol 2018;9:1206. [PMID: 29928268 DOI: 10.3389/fmicb.2018.01206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Lee-Tsai YL, Luna-Santiago R, Demichelis-Gómez R, Ponce-de-León A, Ochoa-Hein E, Tamez-Torres KM, Bourlon MT, Bourlon C. Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases. Blood Res 2019;54:120-4. [PMID: 31309090 DOI: 10.5045/br.2019.54.2.120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Scott MM, Liang SY. Infections in Older Adults. Emerg Med Clin North Am 2021;39:379-94. [PMID: 33863466 DOI: 10.1016/j.emc.2021.01.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Ramos CP, Lopes EO, Diniz AN, Lobato FCF, Vilela EG, Silva ROS. Evaluation of glutamate dehydrogenase (GDH) and toxin A/B rapid tests for Clostridioides (prev. Clostridium) difficile diagnosis in a university hospital in Minas Gerais, Brazil. Braz J Microbiol 2020;51:1139-43. [PMID: 32367261 DOI: 10.1007/s42770-020-00288-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Guery B, Berger P, Gauzit R, Gourdon M, Barbut F, Dafne Study Group, Bémer P, Bessède E, Camou F, Cattoir V, Couzigou C, Descamps D, Dinh A, Laurans C, Lavigne JP, Lechiche C, Leflon-Guibout V, Le Monnier A, Levast M, Mootien JY, N'Guyen Y, Piroth L, Prazuck T, Rogeaux O, Roux AL, Vachée A, Vernet Garnier V, Wallet F; DAFNE study group. A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. J Int Med Res 2021;49:3000605211021278. [PMID: 34162264 DOI: 10.1177/03000605211021278] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol 2021;52:1937-49. [PMID: 34455573 DOI: 10.1007/s42770-021-00563-7] [Reference Citation Analysis]
22 Conrad MA, Kelsen JR. Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease: A Clinician's Dilemma. J Pediatric Infect Dis Soc 2021:piab069. [PMID: 34343321 DOI: 10.1093/jpids/piab069] [Reference Citation Analysis]
23 Grimmond T, Neelakanta A, Miller B, Saiyed A, Gill P, Cadnum J, Olmsted R, Donskey C, Pate K, Miller K. A microbiological study to investigate the carriage and transmission-potential of Clostridium difficile spores on single-use and reusable sharps containers. Am J Infect Control 2018;46:1154-9. [PMID: 29801963 DOI: 10.1016/j.ajic.2018.04.206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis 2021;21:456. [PMID: 34016040 DOI: 10.1186/s12879-021-06147-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Shah T, Baloch Z, Shah Z, Cui X, Xia X. The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases. Int J Mol Sci 2021;22:6597. [PMID: 34202945 DOI: 10.3390/ijms22126597] [Reference Citation Analysis]
26 Stachulski AV, Taujanskas J, Pate SL, Rajoli RKR, Aljayyoussi G, Pennington SH, Ward SA, Hong WD, Biagini GA, Owen A, Nixon GL, Leung SC, O'Neill PM. Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? ACS Infect Dis 2021;7:1317-31. [PMID: 33352056 DOI: 10.1021/acsinfecdis.0c00478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Dubberke ER, Gerding DN, Kelly CP, Garey KW, Rahav G, Mosley A, Tipping R, Dorr MB. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection. Open Forum Infect Dis 2020;7:ofaa157. [PMID: 32523972 DOI: 10.1093/ofid/ofaa157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
28 [DOI: 10.1101/543819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Almutairi MS, Gonzales-Luna AJ, Alnezary FS, Fallatah SB, Alam MJ, Begum K, Garey KW. Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe 2021;72:102440. [PMID: 34461273 DOI: 10.1016/j.anaerobe.2021.102440] [Reference Citation Analysis]
30 Sullivan MH, Boggiano VL, Smith KL. Management of difficult-to-treat Clostridioides difficile in a patient with chronic osteomyelitis. BMJ Case Rep 2020;13:e233095. [PMID: 32229549 DOI: 10.1136/bcr-2019-233095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Saran S, Rao NS, Azim A. New and promising anti-bacterials: Can this promise be sustained? J Anaesthesiol Clin Pharmacol 2020;36:13-9. [PMID: 32174651 DOI: 10.4103/joacp.JOACP_113_19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Rauseo AM, Olsen MA, Reske KA, Dubberke ER. Strategies to prevent adverse outcomes following Clostridioides difficile infection in the elderly. Expert Rev Anti Infect Ther 2020;18:203-17. [PMID: 31976779 DOI: 10.1080/14787210.2020.1717950] [Reference Citation Analysis]
33 Coman V, Vodnar DC. Gut microbiota and old age: Modulating factors and interventions for healthy longevity. Exp Gerontol 2020;141:111095. [PMID: 32979504 DOI: 10.1016/j.exger.2020.111095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
34 Pai S, Polgreen PM, Segre AM, Sewell DK, Pemmaraju SV; CDC MInD-Healthcare group. Spatiotemporal clustering of in-hospital Clostridioides difficile infection. Infect Control Hosp Epidemiol 2020;41:418-24. [PMID: 32000873 DOI: 10.1017/ice.2019.350] [Reference Citation Analysis]
35 Rashid T, Haghighi F, Hasan I, Bassères E, Alam MJ, Sharma SV, Lai D, DuPont HL, Garey KW. Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrob Agents Chemother 2019;64:e01031-19. [PMID: 31611365 DOI: 10.1128/AAC.01031-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ramesh MS, Yee J. Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease. Adv Chronic Kidney Dis 2019;26:30-4. [PMID: 30876614 DOI: 10.1053/j.ackd.2019.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Enoch DA, Murray-Thomas T, Adomakoh N, Dedman D, Georgopali A, Francis NA, Karas A. Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England. J Hosp Infect 2020;106:793-803. [PMID: 32987118 DOI: 10.1016/j.jhin.2020.09.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Limketkai BN, Hendler S, Ting P, Parian AM. Fecal Microbiota Transplantation for the Critically Ill Patient. Nutrition in Clinical Practice 2019;34:73-9. [DOI: 10.1002/ncp.10228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
39 Garneau JR, Abou Chakra CN, Fortier LC, Labbé AC, Simor AE, Gold W, Muller M, McGeer A, Powis J, Katz K, Pépin J, Valiquette L. Multilocus Variable-Number Tandem-Repeat Analysis of Clostridioides difficile Clusters in Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. J Clin Microbiol 2019;57:e01724-18. [PMID: 30760531 DOI: 10.1128/JCM.01724-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
40 Bhattacharyya M, Debnath AK, Todi SK. Clostridium difficile and Antibiotic-associated Diarrhea. Indian J Crit Care Med 2020;24:S162-7. [PMID: 33354035 DOI: 10.5005/jp-journals-10071-23619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Karyal C, Hughes J, Kelly ML, Luckett JC, Kaye PV, Cockayne A, Minton NP, Griffin R. Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. Microorganisms 2021;9:306. [PMID: 33540694 DOI: 10.3390/microorganisms9020306] [Reference Citation Analysis]
42 Abutaleb NS, Seleem MN. Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections. Antimicrob Agents Chemother 2020;64:e02115-19. [PMID: 32253206 DOI: 10.1128/AAC.02115-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
43 Maestri AC, Raboni SM, Morales HMP, Ferrari LF, Tuon FFB, Losso A, Marconi C, Nogueira KDS. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil. Anaerobe 2020;64:102238. [PMID: 32717474 DOI: 10.1016/j.anaerobe.2020.102238] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Jan N, Hays RA, Oakland DN, Kumar P, Ramakrishnan G, Behm BW, Petri WA Jr, Marie C. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile. mSphere 2021;6:e0066921. [PMID: 34704776 DOI: 10.1128/mSphere.00669-21] [Reference Citation Analysis]
45 Ramos CP, Lopes EO, Oliveira Júnior CA, Diniz AN, Lobato FCF, Silva ROS. Immunochromatographic test and ELISA for the detection of glutamate dehydrogenase (GDH) and A/B toxins as an alternative for the diagnosis of Clostridioides (Clostridium) difficile-associated diarrhea in foals and neonatal piglets. Braz J Microbiol 2020;51:1459-62. [PMID: 32363568 DOI: 10.1007/s42770-020-00275-4] [Reference Citation Analysis]
46 Choy A, Freedberg DE. Impact of microbiome-based interventions on gastrointestinal pathogen colonization in the intensive care unit. Therap Adv Gastroenterol 2020;13:1756284820939447. [PMID: 32733601 DOI: 10.1177/1756284820939447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Zaver HB, Moktan VP, Harper EP, Bali A, Nasir A, Foulks C, Kuhlman J, Green M, Algan GA, Parth HC, Wu-Ballis M, DiCicco S, Smith BT, Owen RN, Mai LS, Spiros SL, Griffis J, Ramsey Walker DT, Hata DJ, Oring JM, Powers HR, Bosch W. Reduction in Health Care Facility-Onset Clostridioides difficile Infection: A Quality Improvement Initiative. Mayo Clin Proc Innov Qual Outcomes 2021;5:1066-74. [PMID: 34820598 DOI: 10.1016/j.mayocpiqo.2021.09.004] [Reference Citation Analysis]
48 Kwon JH, O'Neil CA, Hink T, Reske KA, Bosserman RE, Dubberke ER, Burnham CD. Alternative Causes of Infectious Diarrhea in Patients with Negative Tests for Clostridoides Difficile. J Appl Lab Med 2021:jfab110. [PMID: 34609483 DOI: 10.1093/jalm/jfab110] [Reference Citation Analysis]
49 Navalkele BD, Polistico J, Sandhu A, Awali R, Krishna A, Chandramohan S, Tillotson G, Chopra T. Clinical outcomes after faecal microbiota transplant by retention enema in both immunocompetent and immunocompromised patients with recurrent Clostridioides difficile infections at an academic medical centre. J Hosp Infect 2020;106:643-8. [PMID: 32991940 DOI: 10.1016/j.jhin.2020.09.027] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Bader MS, Hawboldt J, Main C, Mertz D, Loeb M, Farrell A, Joyce J. Review of high dose vancomycin in the treatment of Clostridioides difficile infection. Infect Dis (Lond) 2020;52:847-57. [PMID: 32744879 DOI: 10.1080/23744235.2020.1800080] [Reference Citation Analysis]
51 Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care 2022;12:3. [PMID: 34985651 DOI: 10.1186/s13613-021-00976-5] [Reference Citation Analysis]
52 Carlson TJ, Blasingame D, Gonzales-Luna AJ, Alnezary F, Garey KW. Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe 2020;62:102142. [PMID: 32007682 DOI: 10.1016/j.anaerobe.2019.102142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Luc CM, Olson D, Banach DB, Clogher P, Hadler J. Evaluation of Connecticut medical providers' concordance with 2017 IDSA/SHEA Clostridioides difficile treatment guidelines in New Haven County, 2018-2019. Infect Control Hosp Epidemiol 2021;42:549-56. [PMID: 33234174 DOI: 10.1017/ice.2020.1237] [Reference Citation Analysis]
54 Hudson SL, Arnoczy G, Gibson H, Thurber C, Lee J, Kessell A. Probiotic use as prophylaxis for Clostridium difficile-associated diarrhea in a community hospital. Am J Infect Control 2019;47:1028-9. [PMID: 30665779 DOI: 10.1016/j.ajic.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Ravi C, Glass NE, Josyabhatla R, Monteiro I, Sinha V, Kondamudi N. A Rare Cause of Septic Shock in the Emergency Department in an Intellectually-Disabled Child. J Emerg Med 2020;58:e79-82. [PMID: 31708322 DOI: 10.1016/j.jemermed.2019.09.031] [Reference Citation Analysis]
56 Gkartziou F, Giormezis N, Spiliopoulou I, Antimisiaris SG. Nanobiosystems for Antimicrobial Drug-Resistant Infections. Nanomaterials (Basel) 2021;11:1075. [PMID: 33922004 DOI: 10.3390/nano11051075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Markovic S, Jankovic M, Kalaba A, Zogovic B, Sreckovic SS. Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series. Cureus 2021;13:e19019. [PMID: 34824934 DOI: 10.7759/cureus.19019] [Reference Citation Analysis]
58 Cortés P, Bi Y, Stancampiano F, Valery JR, Cooper JH, Harris DM. Clostridioides Difficile Infection: A comprehensive review for primary providers. Rom J Intern Med 2021. [PMID: 33713592 DOI: 10.2478/rjim-2021-0010] [Reference Citation Analysis]
59 Shoaei P, Shojaei H, Shirani K. Phenotypic and Genotypic Characteristics of Clostridium difficile Isolates in Patients with Type 2 Diabetes in Iran. Infect Drug Resist 2020;13:683-90. [PMID: 32161476 DOI: 10.2147/IDR.S225829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Aguilar RC, Salmanton-García J, Carney J, Böll B, Kochanek M, Jazmati N, Cornely OA, Vehreschild MJGT. Clostridioides difficile infections in the intensive care unit: a monocentric cohort study. Infection 2020;48:421-7. [PMID: 32212102 DOI: 10.1007/s15010-020-01413-8] [Reference Citation Analysis]
61 Wong D, Nanda N. Clostridium difficile disease in solid organ transplant recipients: a recommended treatment paradigm. Curr Opin Organ Transplant 2020;25:357-63. [PMID: 32618715 DOI: 10.1097/MOT.0000000000000778] [Reference Citation Analysis]
62 Zellmer C, Sater MRA, Huntley MH, Osman M, Olesen SW, Ramakrishna B. Shiga Toxin–Producing Escherichia coli Transmission via Fecal Microbiota Transplant. Clinical Infectious Diseases 2021;72:e876-80. [DOI: 10.1093/cid/ciaa1486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
63 McCort MN, Oehler C, Enriquez M, Landon E, Nguyen CT, Pettit NN, Ridgway J, Pisano J. Universal molecular Clostridioides difficile screening and overtreatment in solid organ transplant recipients. Transpl Infect Dis 2020;22:e13375. [PMID: 32569411 DOI: 10.1111/tid.13375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Yang Z, Huang Q, Qin J, Zhang X, Jian Y, Lv H, Liu Q, Li M. Molecular Epidemiology and Risk Factors of Clostridium difficile ST81 Infection in a Teaching Hospital in Eastern China. Front Cell Infect Microbiol 2020;10:578098. [PMID: 33425775 DOI: 10.3389/fcimb.2020.578098] [Reference Citation Analysis]
65 Khanna S. Fecal transplant clinical trials for Clostridioides difficile: an interview with Sahil Khanna. Future Microbiol 2020;15:709-12. [PMID: 32677453 DOI: 10.2217/fmb-2020-0102] [Reference Citation Analysis]
66 Polage CR, Turner NA. Uncovering the Harms of Treating Clostridioides difficile Colonization. mSphere 2021;6:e01296-20. [PMID: 33441413 DOI: 10.1128/mSphere.01296-20] [Reference Citation Analysis]
67 Khattab RA, Ahmed NA, Ragab YM, Rasmy SA. Bacteria producing antimicrobials against Clostridium difficile isolated from human stool. Anaerobe 2020;63:102206. [PMID: 32339663 DOI: 10.1016/j.anaerobe.2020.102206] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Puro N, Joseph R, Zengul FD, Cochran KJ, Camins BC, Ray M. Predictors of Hospital-Acquired Clostridioides difficile Infection: A Systematic Review. J Healthc Qual 2020;42:127-35. [PMID: 31821178 DOI: 10.1097/JHQ.0000000000000236] [Reference Citation Analysis]
69 Dubberke ER, Reske KA, Hink T, Kwon JH, Cass C, Bongu J, Burnham CD, Henderson JP. Clostridium difficile colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea. Infect Control Hosp Epidemiol 2018;39:1330-3. [PMID: 30226126 DOI: 10.1017/ice.2018.225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Tieu JD, Williams RJ, Skrepnek GH, Gentry CA. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. J Clin Pharm Ther 2019;44:220-8. [DOI: 10.1111/jcpt.12771] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
71 Miranda-Katz M, Parmar D, Dang R, Alabaster A, Greenhow TL. Epidemiology and Risk Factors for Community Associated Clostridioides difficile in Children. J Pediatr 2020;221:99-106. [PMID: 32171559 DOI: 10.1016/j.jpeds.2020.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Gonzales-Luna AJ, Carlson TJ, Garey KW. Antibiotic Therapies for Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc 2021;10:S52-7. [PMID: 34791393 DOI: 10.1093/jpids/piab059] [Reference Citation Analysis]
73 Tran MN, Kullar R, Goldstein EJC. Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection. Expert Opinion on Investigational Drugs 2019;28:323-35. [DOI: 10.1080/13543784.2019.1581763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
74 Wilcox MH, McGovern BH, Hecht GA. The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis. Open Forum Infect Dis 2020;7:ofaa114. [PMID: 32405509 DOI: 10.1093/ofid/ofaa114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
75 Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS One 2019;14:e0214222. [PMID: 31013271 DOI: 10.1371/journal.pone.0214222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
76 Murphy MM, Patatanian E, Gales MA. Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review. Ther Adv Infect Dis 2018;5:111-9. [PMID: 30430009 DOI: 10.1177/2049936118798276] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
77 Prohaska L, Mahmoudjafari Z, Shune L, Singh A, Lin T, Abhyankar S, Ganguly S, Grauer D, McGuirk J, Clough L. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther 2018;11:233-40. [PMID: 29928848 DOI: 10.1016/j.hemonc.2018.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
78 Waker E, Ambrozkiewicz F, Kulecka M, Paziewska A, Skubisz K, Cybula P, Targoński Ł, Mikula M, Walewski J, Ostrowski J. High Prevalence of Genetically Related Clostridium Difficile Strains at a Single Hemato-Oncology Ward Over 10 Years. Front Microbiol 2020;11:1618. [PMID: 32793147 DOI: 10.3389/fmicb.2020.01618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211016248. [PMID: 34093740 DOI: 10.1177/17562848211016248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Morrisette T, Van Matre AG, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, Benamu E, Kaiser JN, Barber GR, Chase S, Tobin J, Fish DN, Gutman JA. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population. Biol Blood Marrow Transplant 2019;25:2091-7. [PMID: 31255741 DOI: 10.1016/j.bbmt.2019.06.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
81 Ke S, Pollock NR, Wang XW, Chen X, Daugherty K, Lin Q, Xu H, Garey KW, Gonzales-Luna AJ, Kelly CP, Liu YY. Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes 2021;13:1-18. [PMID: 34132169 DOI: 10.1080/19490976.2021.1935186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Tilton CS, Johnson SW. Development of a risk prediction model for hospital-onset Clostridium difficile infection in patients receiving systemic antibiotics. American Journal of Infection Control 2019;47:280-4. [DOI: 10.1016/j.ajic.2018.08.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Giacobbe DR, Corcione S, Salsano A, Del Puente F, Mornese Pinna S, De Rosa FG, Mikulska M, Santini F, Viscoli C. Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opin Pharmacother 2019;20:751-72. [PMID: 30785333 DOI: 10.1080/14656566.2019.1574753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
84 Gulati M, Singh SK, Corrie L, Kaur IP, Chandwani L. Delivery routes for faecal microbiota transplants: Available, anticipated and aspired. Pharmacological Research 2020;159:104954. [DOI: 10.1016/j.phrs.2020.104954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
85 Box MJ, Ortwine KN, Goicoechea M; Scripps Antimicrobial Stewardship Program (SASP). No Impact of Probiotics to Reduce Clostridium difficile Infection in Hospitalized Patients: A Real-world Experience. Open Forum Infect Dis 2018;5:ofy192. [PMID: 30568976 DOI: 10.1093/ofid/ofy192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
86 Tawam D, Baladi M, Jungsuwadee P, Earl G, Han J. The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection. Innov Pharm 2021;12. [PMID: 34007671 DOI: 10.24926/iip.v12i1.3439] [Reference Citation Analysis]
87 Singhal T, Shah S, Tejam R, Thakkar P. Incidence, epidemiology and control of Clostridium difficile infection in a tertiary care private hospital in India. Indian J Med Microbiol 2018;36:381-4. [PMID: 30429391 DOI: 10.4103/ijmm.IJMM_18_340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
88 Kuijper EJ, Allegretii J, Hawkey P, Sokol H, Goldenberg S, Ianiro G, Gasbarrini A, Kump P, Costello SP, Keller J, Vehreschild MJGT. A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. Lancet Infect Dis 2019;19:1161-2. [PMID: 31657769 DOI: 10.1016/S1473-3099(19)30545-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
89 Murray B, Wolfe C, Marra A, Pillar C, Shinabarger D. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile. J Antimicrob Chemother 2020;75:2149-55. [PMID: 32285102 DOI: 10.1093/jac/dkaa134] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Bar-Yoseph H, Daoud H, Ben Hur D, Chowers Y, Waterman M. Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with Clostridioides difficile infection? Int J Colorectal Dis 2020;35:513-9. [PMID: 31927638 DOI: 10.1007/s00384-019-03502-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
91 Khader K, Munoz-Price LS, Hanson R, Stevens V, Keegan LT, Thomas A, Pezzin LE, Nattinger A, Singh S, Samore MH. Transmission Dynamics of Clostridioides difficile in 2 High-Acuity Hospital Units. Clin Infect Dis 2021;72:S1-7. [PMID: 33512524 DOI: 10.1093/cid/ciaa1580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Schwabkey ZI, Jenq RR. Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation. Annu Rev Med 2020;71:137-48. [PMID: 31986084 DOI: 10.1146/annurev-med-052918-122440] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
93 McDonald EG, Dendukuri N, Frenette C, Lee TC. Time-Series Analysis of Health Care-Associated Infections in a New Hospital With All Private Rooms. JAMA Intern Med 2019;179:1501-6. [PMID: 31424489 DOI: 10.1001/jamainternmed.2019.2798] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
94 Morgan M, Farrell T, Ndubizu GU, Farrell TJ. Colonic lavage in treatment of refractory Clostridium difficile infection: an adaptation of the Pittsburgh protocol. J Surg Case Rep 2020;2020:rjaa159. [PMID: 32699601 DOI: 10.1093/jscr/rjaa159] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Schwenk HT, Bio LL, Kruger JF, Banaei N. Clinical Impact of Clostridium difficile PCR Cycle Threshold-Predicted Toxin Reporting in Pediatric Patients. J Pediatric Infect Dis Soc 2020;9:44-50. [PMID: 30476169 DOI: 10.1093/jpids/piy117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
96 Ojha SC, Phanchana M, Harnvoravongchai P, Chankhamhaengdecha S, Singhakaew S, Ounjai P, Janvilisri T. Teicoplanin Suppresses Vegetative Clostridioides difficile and Spore Outgrowth. Antibiotics (Basel) 2021;10:984. [PMID: 34439034 DOI: 10.3390/antibiotics10080984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Guery B, Barbut F, Tschudin-Sutter S. Diagnostic and therapy of severe Clostridioides difficile infections in the ICU. Curr Opin Crit Care 2020;26:450-8. [PMID: 32739967 DOI: 10.1097/MCC.0000000000000753] [Reference Citation Analysis]
98 AlJindan R, AlEraky DM, Borgio JF, AbdulAzeez S, Abdalhamid B, Mahmoud N, Farhat M. Diagnostic deficiencies of C. difficile infection among patients in a tertiary hospital in Saudi Arabia: A laboratory-based case series. Saudi J Biol Sci 2021;28:4472-7. [PMID: 34354432 DOI: 10.1016/j.sjbs.2021.04.044] [Reference Citation Analysis]
99 Szabo BG, Duma L, Lenart KS, Kiss R, Vad E, Petrik BR, Ostorhazi E, Kadar B. Characteristics and predictors of treatment failure with intravenous tigecycline monotherapy among adult patients with severe Clostridioides (Clostridium) difficile infection: a single-centre observational cohort study. Diagn Microbiol Infect Dis 2021;99:115231. [PMID: 33099134 DOI: 10.1016/j.diagmicrobio.2020.115231] [Reference Citation Analysis]
100 Zhou S, Nagel JL, Kaye KS, LaPlante KL, Albin OR, Pogue JM. Antimicrobial Stewardship and the Infection Control Practitioner: A Natural Alliance. Infect Dis Clin North Am 2021;35:771-87. [PMID: 34362543 DOI: 10.1016/j.idc.2021.04.011] [Reference Citation Analysis]
101 Wu Q, Savidge TC. Systems approaches for the clinical diagnosis of Clostridioides difficile infection. Transl Res 2020;220:57-67. [PMID: 32272094 DOI: 10.1016/j.trsl.2020.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Sommermeyer H, Pituch HM, Wultanska D, Wojtyla-Buciora P, Piatek J, Bernatek M. Inhibition of Quinolone- and Multi-Drug-Resistant Clostridioides Difficile Strains by Multi Strain Synbiotics-An Option for Diarrhea Management in Nursing Facilities. Int J Environ Res Public Health 2021;18:5871. [PMID: 34070727 DOI: 10.3390/ijerph18115871] [Reference Citation Analysis]
103 Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV. Antimicrobial resistance in Clostridium difficile ribotype 017. Expert Rev Anti Infect Ther 2020;18:17-25. [PMID: 31800331 DOI: 10.1080/14787210.2020.1701436] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
104 Scherz V, Greub G, Bertelli C. Building up a clinical microbiota profiling: a quality framework proposal. Crit Rev Microbiol 2021;:1-20. [PMID: 34752719 DOI: 10.1080/1040841X.2021.1975642] [Reference Citation Analysis]
105 Kulaylat AS, Buonomo EL, Stewart DB. Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy-Reply. JAMA Surg 2019;154:464-5. [PMID: 30758488 DOI: 10.1001/jamasurg.2018.5596] [Reference Citation Analysis]
106 Mamoon L, Olesen SW. Fecal Microbiota Transplants Annually and Their Positive Clinical Impact. Clin Transl Gastroenterol 2020;11:e00247. [PMID: 33259159 DOI: 10.14309/ctg.0000000000000247] [Reference Citation Analysis]
107 Barker AK, Scaria E, Safdar N, Alagoz O. Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection. JAMA Netw Open 2020;3:e2012522. [PMID: 32789514 DOI: 10.1001/jamanetworkopen.2020.12522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
108 Tougas SR, Lodha N, Vandermeer B, Lorenzetti DL, Tarr PI, Tarr GAM, Chui L, Vanderkooi OG, Freedman SB. Prevalence of Detection of Clostridioides difficile Among Asymptomatic Children: A Systematic Review and Meta-analysis. JAMA Pediatr 2021;:e212328. [PMID: 34338715 DOI: 10.1001/jamapediatrics.2021.2328] [Reference Citation Analysis]
109 Herman DJ, Sarabia A, Chan H, Graham C. Changing Results to Change Results: Nudging Antimicrobial Prescribing for Clostridium difficile. Open Forum Infect Dis 2021;8:ofaa605. [PMID: 34095335 DOI: 10.1093/ofid/ofaa605] [Reference Citation Analysis]
110 Lee HW, Han SB, Rhim JW. Application of a Multiplex Polymerase Chain Reaction Test for Diagnosing Bacterial Enteritis in Children in a Real-Life Clinical Setting. Children (Basel) 2021;8:538. [PMID: 34202436 DOI: 10.3390/children8070538] [Reference Citation Analysis]
111 Turner NA, Warren BG, Gergen-Teague MF, Addison RM, Addison B, Rutala WA, Weber DJ, Sexton DJ, Anderson DJ. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination with Clostridioides difficile. Clin Infect Dis 2021:ciab473. [PMID: 34017999 DOI: 10.1093/cid/ciab473] [Reference Citation Analysis]
112 Milenković B, Šuljagić V, Perić A, Dragojević-Simić V, Tarabar O, Milanović M, Putić V, Tomić D, Miljković B, Vezmar Kovačević S. Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. Eur J Hosp Pharm 2021:ejhpharm-2020-002574. [PMID: 33579720 DOI: 10.1136/ejhpharm-2020-002574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Kociolek LK. Moving the Needle on Clostridioides difficile Research in Children: A Major Step Forward but Challenges Remain. Clin Infect Dis 2020;71:2589-91. [PMID: 31773137 DOI: 10.1093/cid/ciz1154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Khanna S, Kraft CS. The interplay of SARS-CoV-2 and Clostridioides difficile infection. Future Microbiol 2021;16:439-43. [PMID: 33847139 DOI: 10.2217/fmb-2020-0275] [Reference Citation Analysis]
115 Robilotti E, Huang W, Babady NE, Chen D, Kamboj M. Transmission of Clostridioides difficile infection (CDI) from patients less than 3 years of age in a pediatric oncology setting. Infect Control Hosp Epidemiol 2020;41:233-6. [PMID: 31896369 DOI: 10.1017/ice.2019.360] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Wombwell E, Patterson ME, Bransteitter B, Gillen LR. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection. Clinical Infectious Diseases 2020. [DOI: 10.1093/cid/ciaa808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
117 Kwiatkowski S, Mulugeta S, Davis S, Kenney R, Kalus J, Walton L, Patel N. Optimizing preoperative antibiotics in patients with β-lactam allergies: A role for pharmacy. Am J Health Syst Pharm 2021:zxab218. [PMID: 34037708 DOI: 10.1093/ajhp/zxab218] [Reference Citation Analysis]
118 Abutaleb NS, Seleem MN. In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection. Sci Rep 2021;11:7093. [PMID: 33782498 DOI: 10.1038/s41598-021-86595-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 de Melo Pacífico D, Costa CL, Moura H, Barr JR, Maia GA, Filho VB, Moreira RS, Wagner G, Domingues RMCP, Quesada-Gómez C, de Oliveira Ferreira E, de Castro Brito GA. Exoproteomic analysis of two MLST clade 2 strains of Clostridioides difficile from Latin America reveal close similarities. Sci Rep 2021;11:13273. [PMID: 34168208 DOI: 10.1038/s41598-021-92684-0] [Reference Citation Analysis]
120 Skinner AM, Phillips ST, Merrigan MM, O'Leary KJ, Sambol SP, Siddiqui F, Peterson LR, Gerding DN, Johnson S. The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile. J Clin Med 2020;10:E96. [PMID: 33396595 DOI: 10.3390/jcm10010096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
121 Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res 2021;19:265-74. [PMID: 32806873 DOI: 10.5217/ir.2020.00045] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
122 Hong S, Knight DR, Riley TV. The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection. Microbiol Aust 2019;40:77. [DOI: 10.1071/ma19022] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Bowman JA, Utter GH. Evolving Strategies to Manage Clostridium difficile Colitis. J Gastrointest Surg 2020;24:484-91. [PMID: 31768834 DOI: 10.1007/s11605-019-04478-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Acquisto NM, Slocum GW, Bilhimer MH, Awad NI, Justice SB, Kelly GF, Makhoul T, Patanwala AE, Peksa GD, Porter B, Truoccolo DMS, Treu CN, Weant KA, Thomas MC. Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update. Am J Health Syst Pharm 2020;77:1284-335. [PMID: 32766731 DOI: 10.1093/ajhp/zxaa178] [Reference Citation Analysis]
125 Seekatz AM, Wolfrum E, DeWald CM, Putler RKB, Vendrov KC, Rao K, Young VB. Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. Anaerobe 2018;53:74-81. [PMID: 29859301 DOI: 10.1016/j.anaerobe.2018.05.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
126 Doan TH, Yen-Nicolaÿ S, Bernet-Camard MF, Martin-Verstraete I, Péchiné S. Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility. PLoS One 2020;15:e0241903. [PMID: 33166349 DOI: 10.1371/journal.pone.0241903] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Sedano R, Nuñez P, Quera R. DIAGNOSTIC AND MANAGEMENT APPROACH TO POUCHITIS IN INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2020;57:100-6. [PMID: 32294743 DOI: 10.1590/S0004-2803.202000000-17] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Lee AA, Rao K, Limsrivilai J, Gillilland M, Malamet B, Briggs E, Young VB, Higgins PDR. Temporal Gut Microbial Changes Predict Recurrent Clostridiodes Difficile Infection in Patients With and Without Ulcerative Colitis. Inflamm Bowel Dis 2020;26:1748-58. [PMID: 31971239 DOI: 10.1093/ibd/izz335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
129 Garza-González E, Mendoza-Olazarán S, Morfin-Otero R, Ramírez-Fontes A, Rodríguez-Zulueta P, Flores-Treviño S, Bocanegra-Ibarias P, Maldonado-Garza H, Camacho-Ortiz A. Intestinal Microbiome Changes in Fecal Microbiota Transplant (FMT) vs. FMT Enriched with Lactobacillus in the Treatment of Recurrent Clostridioides difficile Infection. Can J Gastroenterol Hepatol 2019;2019:4549298. [PMID: 31976311 DOI: 10.1155/2019/4549298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
130 Tran NN, Mills JP, Zimmerman C, Gandhi TN, Tribble AC, Petty LA, Nagel J, Brancaccio A, Scappaticci G, Patel T, Dillman NO, Regal R, Klein KC, Washer L, Marshall VD, Sweeney J, Rao K, Eschenauer GA. Incorporating preauthorization into antimicrobial stewardship pharmacist workflow reduces Clostridioides difficile and gastrointestinal panel testing. Infect Control Hosp Epidemiol 2020;41:1136-41. [PMID: 32489156 DOI: 10.1017/ice.2020.236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Peseski AM, McClean M, Green SD, Beeler C, Konig H. Management of fever and neutropenia in the adult patient with acute myeloid leukemia. Expert Rev Anti Infect Ther 2021;19:359-78. [PMID: 32892669 DOI: 10.1080/14787210.2020.1820863] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Charshafian S, Liang SY. Rapid Fire: Infectious Disease Emergencies in Patients with Cancer. Emerg Med Clin North Am 2018;36:493-516. [PMID: 30037437 DOI: 10.1016/j.emc.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
133 Rac H, Gould AP, Eiland LS, Griffin B, McLaughlin M, Stover KR, Bland CM, Bookstaver PB. Common Bacterial and Viral Infections: Review of Management in the Pregnant Patient. Ann Pharmacother 2019;53:639-51. [PMID: 30556401 DOI: 10.1177/1060028018817935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
134 Kuon C, Wannier R, Sterken D, Fang MC, Wolf J, Prasad PA. Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients. Mayo Clin Proc Innov Qual Outcomes 2020;4:792-800. [PMID: 33367215 DOI: 10.1016/j.mayocpiqo.2020.06.005] [Reference Citation Analysis]
135 Iriana S, Sharma S, McDonough S, Zarate ER, Adler DG. Outcomes among inpatients with cirrhosis and Clostridioides difficile infection in the modern era: results from an analysis of the National Inpatient Sample. Ann Gastroenterol 2021;34:721-7. [PMID: 34475744 DOI: 10.20524/aog.2021.0646] [Reference Citation Analysis]
136 Jose S, Mukherjee A, Horrigan O, Setchell KDR, Zhang W, Moreno-Fernandez ME, Andersen H, Sharma D, Haslam DB, Divanovic S, Madan R. Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice. Mucosal Immunol 2021;14:500-10. [PMID: 32811993 DOI: 10.1038/s41385-020-00338-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Razim A, Pacyga K, Martirosian G, Szuba A, Gamian A, Myc A, Górska S. Mapping Epitopes of a Novel Peptidoglycan Cross-Linking Enzyme Cwp22 Recognized by Human Sera Obtained from Patients with Clostridioides difficile Infection and Cord Blood. Microorganisms 2019;7:E565. [PMID: 31739602 DOI: 10.3390/microorganisms7110565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Greiner B, Essex R, Wheeler D. An analysis of research quality underlying IDSA clinical practice guidelines: a cross-sectional study. J Osteopath Med 2021;121:319-23. [PMID: 33449070 DOI: 10.1515/jom-2020-0081] [Reference Citation Analysis]
139 Jiang Y, Sarpong EM, Sears P, Obi EN. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Infect Dis Ther 2021. [PMID: 34292496 DOI: 10.1007/s40121-021-00480-0] [Reference Citation Analysis]
140 Karlovich NS, Sata SS, Griffith B, Coop A, Kalu IC, Engemann JJ, Seidelman J, Turner NA, Polage CR, Smith BA, Lewis SS. In pursuit of the holy grail: Improving C. difficile testing appropriateness with iterative electronic health record clinical decision support and targeted test restriction. Infect Control Hosp Epidemiol 2021;:1-8. [PMID: 34085622 DOI: 10.1017/ice.2021.228] [Reference Citation Analysis]
141 Mutai WC, Mureithi MW, Anzala O, Revathi G, Kullin B, Burugu M, Kyany'a C, Odoyo E, Otieno P, Musila L. High Prevalence of Multidrug-Resistant Clostridioides difficile Following Extensive Use of Antimicrobials in Hospitalized Patients in Kenya. Front Cell Infect Microbiol 2020;10:604986. [PMID: 33628744 DOI: 10.3389/fcimb.2020.604986] [Reference Citation Analysis]
142 Hansen G, Young S, Wu AHB, Herding E, Nordberg V, Mills R, Griego-Fullbright C, Wagner A, Ong CM, Lewis S, Yoon J, Estis J, Sandlund J, Friedland E, Carroll KC. Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay. J Clin Microbiol 2019;57:e00719-19. [PMID: 31434724 DOI: 10.1128/JCM.00719-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
143 Vaughn JL, Balada-Llasat JM, Lamprecht M, Huang Y, Anghelina M, El Boghdadly Z, Bishop-Hill K, Childs R, Pancholi P, Andritsos LA. Detection of toxigenic Clostridium difficile colonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation. J Med Microbiol 2018;67:976-81. [PMID: 29863458 DOI: 10.1099/jmm.0.000774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
144 Kociolek LK, Davidovics ZH, Kahn SA, Kellermayer R. Response to: Treatment of (Recurrent) Clostridioides difficile Infections in Children and Adults. J Pediatr Gastroenterol Nutr 2019;69:e58-9. [PMID: 31169659 DOI: 10.1097/MPG.0000000000002388] [Reference Citation Analysis]
145 Woodworth MH, Hayden MK, Young VB, Kwon JH. The Role of Fecal Microbiota Transplantation in Reducing Intestinal Colonization With Antibiotic-Resistant Organisms: The Current Landscape and Future Directions. Open Forum Infect Dis 2019;6:ofz288. [PMID: 31363779 DOI: 10.1093/ofid/ofz288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
146 Tariq R, Disbrow MB, Dibaise JK, Orenstein R, Saha S, Solanky D, Loftus EV, Pardi DS, Khanna S. Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26:1415-1420. [PMID: 31821444 DOI: 10.1093/ibd/izz299] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
147 Gonzales-Luna AJ, Carlson TJ, Dotson KM, Poblete K, Costa G, Miranda J, Lancaster C, Walk ST, Tupy S, Begum K, Alam MJ, Garey KW. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect 2020;9:341-7. [PMID: 32037964 DOI: 10.1080/22221751.2020.1721335] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
148 White NC, Mendo-Lopez R, Papamichael K, Cuddemi CA, Barrett C, Daugherty K, Pollock N, Kelly CP, Alonso CD. Laxative Use Does Not Preclude Diagnosis or Reduce Disease Severity in Clostridiodes difficile Infection. Clin Infect Dis 2020;71:1472-8. [PMID: 31584632 DOI: 10.1093/cid/ciz978] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
149 Chastain CA, Klopfenstein N, Serezani CH, Aronoff DM. A Clinical Review of Diabetic Foot Infections. Clin Podiatr Med Surg 2019;36:381-95. [PMID: 31079605 DOI: 10.1016/j.cpm.2019.02.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
150 Xuan S, Zangwill KM, Ni W, Ma J, Hay JW. Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection. J Gen Intern Med 2020;35:1102-10. [PMID: 32016703 DOI: 10.1007/s11606-019-05487-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Katzer KC, Hagel S, Reuken PA, Bruns T, Stallmach A. Development and validation of a simple and robust model to predict 30-day mortality in patients with Clostridioides difficile-associated enterocolitis. BMJ Open Gastroenterol 2020;7:e000468. [PMID: 32912845 DOI: 10.1136/bmjgast-2020-000468] [Reference Citation Analysis]
152 Stevens VW, Khader K, Echevarria K, Nelson RE, Zhang Y, Jones M, Timbrook TT, Samore MH, Rubin MA. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci. Clinical Infectious Diseases 2020;71:645-51. [DOI: 10.1093/cid/ciz871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
153 Azimirad M, Krutova M, Balaii H, Kodori M, Shahrokh S, Azizi O, Yadegar A, Aghdaei HA, Zali MR. Coexistence of Clostridioides difficile and Staphylococcus aureus in gut of Iranian outpatients with underlying inflammatory bowel disease. Anaerobe 2020;61:102113. [DOI: 10.1016/j.anaerobe.2019.102113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
154 Forrester JD, Colling KP, Diaz JJ, Faliks B, Kim PK, Tessier JM, Tung J, Huston JM. Surgical Infection Society Guidelines for Total Abdominal Colectomy versus Diverting Loop Ileostomy with Antegrade Intra-Colonic Lavage for the Surgical Management of Severe or Fulminant, Non-Perforated Clostridioides difficile Colitis. Surg Infect (Larchmt) 2021. [PMID: 34619068 DOI: 10.1089/sur.2021.126] [Reference Citation Analysis]
155 Parnell JM, Nicholson MR, Kellermayer R, Kahn SA. Pediatric Fecal Microbiota Transplantation in Recurrent Clostridioides Difficile. Pediatr Ann 2021;50:e515-21. [PMID: 34889135 DOI: 10.3928/19382359-20211111-01] [Reference Citation Analysis]
156 Sánchez-Pellicer P, Navarro-López V, González-Tamayo R, Llopis-Ruiz C, Núñez-Delegido E, Ruzafa-Costas B, Navarro-Moratalla L, Agüera-Santos J. Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile. Microorganisms 2021;9:1727. [PMID: 34442805 DOI: 10.3390/microorganisms9081727] [Reference Citation Analysis]
157 Kuriyama A, Jackson JL. Defining metronidazole-induced encephalopathy. J Neurol 2019;266:1272-3. [PMID: 30863892 DOI: 10.1007/s00415-019-09275-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Šamadan L, Jeličić M, Vince A, Papić N. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:780. [PMID: 34198964 DOI: 10.3390/antibiotics10070780] [Reference Citation Analysis]
159 Heudorf U, Berres M, Dogan O, Steul KS. [Legal Obligation to Notify Severe Clostridiodes difficile Infections - Data from Frankfurt am Main, Germany. Overview and Discussion]. Gesundheitswesen 2021. [PMID: 33588443 DOI: 10.1055/a-1330-8293] [Reference Citation Analysis]
160 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
161 D'Souza SM, Houston K, Keenan L, Yoo BS, Parekh PJ, Johnson DA. Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: A paradigm shift from acid to bacteria? World J Gastroenterol 2021; 27(18): 2054-2072 [PMID: 34025064 DOI: 10.3748/wjg.v27.i18.2054] [Reference Citation Analysis]
162 Barker AK, Scaria E, Alagoz O, Sethi AK, Safdar N. Reducing C. difficile in children: An agent-based modeling approach to evaluate intervention effectiveness. Infect Control Hosp Epidemiol 2020;41:522-30. [PMID: 32052722 DOI: 10.1017/ice.2020.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Williamson CHD, Stone NE, Nunnally AE, Hornstra HM, Wagner DM, Roe CC, Vazquez AJ, Nandurkar N, Vinocur J, Terriquez J, Gillece J, Travis J, Lemmer D, Keim P, Sahl JW. A global to local genomics analysis of Clostridioides difficile ST1/RT027 identifies cryptic transmission events in a northern Arizona healthcare network. Microb Genom 2019;5. [PMID: 31107202 DOI: 10.1099/mgen.0.000271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
164 Cançado GGL, Abreu ES, Nardelli MJ, Serwa P, Brachmann M. A cost of illness comparison for toxigenic Clostridioides difficile diagnosis algorithms in developing countries. Anaerobe 2021;70:102390. [PMID: 34058377 DOI: 10.1016/j.anaerobe.2021.102390] [Reference Citation Analysis]
165 Jain S, Clezy K, Mclaws M. Modified glove use for contact precautions: Health care workers’ perceptions and acceptance. American Journal of Infection Control 2019;47:938-44. [DOI: 10.1016/j.ajic.2019.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Keats KR, Stitt TM, Chastain DB, Jivan BP, Matznick E, Waller JL, Clemmons AB. Evaluating Clostridioides difficile infection (CDI) treatment duration in hematology/oncology patients receiving concurrent non-CDI antibiotics. J Oncol Pharm Pract 2021;:1078155221998735. [PMID: 33663290 DOI: 10.1177/1078155221998735] [Reference Citation Analysis]
167 Collison M, Murillo C, Marrs R, Bartlett A, Tesic V, Beavis KG, Landon E, Ridgway JP. Universal screening for Clostridioides difficile at an urban academic medical center. Infect Control Hosp Epidemiol 2021;42:351-2. [PMID: 32959739 DOI: 10.1017/ice.2020.428] [Reference Citation Analysis]
168 Żebrowska P, Łaczmańska I, Łaczmański Ł. Future Directions in Reducing Gastrointestinal Disorders in Children With ASD Using Fecal Microbiota Transplantation. Front Cell Infect Microbiol 2021;11:630052. [PMID: 33718277 DOI: 10.3389/fcimb.2021.630052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Azimirad M, Yadegar A, Gholami F, Shahrokh S, Asadzadeh Aghdaei H, Ianiro G, Suzuki H, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. J Inflamm Res 2020;13:563-70. [PMID: 32982371 DOI: 10.2147/JIR.S265520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Marra AR, Edmond MB, Ford BA, Herwaldt LA, Algwizani AR, Diekema DJ. Impact of 2018 Changes in National Healthcare Safety Network Surveillance for Clostridium difficile Laboratory-Identified Event Reporting. Infect Control Hosp Epidemiol 2018;39:886-8. [DOI: 10.1017/ice.2018.86] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
171 Mendo-Lopez R, Villafuerte-Gálvez J, White N, Mahoney MV, Kelly CP, Alonso CD. Recent developments in the management of recurrent Clostridioides difficile infection. Anaerobe 2020;62:102108. [PMID: 31606481 DOI: 10.1016/j.anaerobe.2019.102108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
172 Wagner JL, Stover KR, Bell AM, Barber KE. Risk factors for development of initial Clostridioides difficile infection. J Glob Antimicrob Resist 2021;25:18-22. [PMID: 33667706 DOI: 10.1016/j.jgar.2021.02.012] [Reference Citation Analysis]
173 Cibulková I, Řehořová V, Hajer J, Duška F. Fecal Microbial Transplantation in Critically Ill Patients-Structured Review and Perspectives. Biomolecules 2021;11:1459. [PMID: 34680092 DOI: 10.3390/biom11101459] [Reference Citation Analysis]
174 Gentry CA, Nguyen PK, Thind S, Kurdgelashvili G, Skrepnek GH, Williams RJ 2nd. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect 2019;25:987-93. [PMID: 30583055 DOI: 10.1016/j.cmi.2018.12.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
175 Aghdassi SJS, Gastmeier P, Behnke M, Hansen S, Kramer TS. Redundant Anaerobic Antimicrobial Prescriptions in German Acute Care Hospitals: Data from a National Point Prevalence Survey. Antibiotics (Basel) 2020;9:E288. [PMID: 32481490 DOI: 10.3390/antibiotics9060288] [Reference Citation Analysis]
176 Dudzicz S, Wiecek A, Adamczak M. Clostridioides difficile Infection in Chronic Kidney Disease-An Overview for Clinicians. J Clin Med 2021;10:E196. [PMID: 33430465 DOI: 10.3390/jcm10020196] [Reference Citation Analysis]
177 Skinner AM, Yu B, Cheknis A, Pacheco SM, Gerding DN, Johnson S. Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase in Clostridioides difficile detection and a trend toward increased strain diversity. Infect Control Hosp Epidemiol 2020;41:1148-53. [PMID: 32576334 DOI: 10.1017/ice.2020.267] [Reference Citation Analysis]
178 Yun JH, Park GE, Ki HK. Correlation between antibiotic consumption and the incidence of healthcare facility-onset Clostridioides difficile infection: a retrospective chart review and analysis. Antimicrob Resist Infect Control 2021;10:117. [PMID: 34362442 DOI: 10.1186/s13756-021-00986-9] [Reference Citation Analysis]
179 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Reference Citation Analysis]
180 Sullivan EL, Majumdar R, Ortiz C, Riggs PK, Crum-Cianflone NF. The impact of changing reflexive to clinician-ordered Clostridioides difficile polymerase chain reaction (PCR) testing for indeterminate cases: Cost savings without associated adverse events. Infect Control Hosp Epidemiol 2020;41:684-90. [PMID: 32279670 DOI: 10.1017/ice.2020.56] [Reference Citation Analysis]
181 Han SH, Yi J, Kim JH, Lee S, Moon HW. Composition of gut microbiota in patients with toxigenic Clostridioides (Clostridium) difficile: Comparison between subgroups according to clinical criteria and toxin gene load. PLoS One 2019;14:e0212626. [PMID: 30785932 DOI: 10.1371/journal.pone.0212626] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
182 Angarone M, Snydman DR; AST ID Community of Practice. Diagnosis and management of diarrhea in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13550. [PMID: 30913334 DOI: 10.1111/ctr.13550] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
183 Mizusawa M, Carroll KC. The future of Clostridioides difficile diagnostics. Curr Opin Infect Dis 2021;34:483-90. [PMID: 34524199 DOI: 10.1097/QCO.0000000000000754] [Reference Citation Analysis]
184 Ghia CJ, Waghela S, Rambhad GS. Systematic Literature Review on Burden of Clostridioides difficile Infection in India. Clin Pathol 2021;14:2632010X211013816. [PMID: 34104883 DOI: 10.1177/2632010X211013816] [Reference Citation Analysis]
185 Schoyer E, Hall K. Environmental Cleaning and Decontamination to Prevent Clostridioides difficile Infection in Health Care Settings: A Systematic Review. J Patient Saf 2020;16:S12-5. [PMID: 32809996 DOI: 10.1097/PTS.0000000000000749] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Malesza IJ, Malesza M, Walkowiak J, Mussin N, Walkowiak D, Aringazina R, Bartkowiak-Wieczorek J, Mądry E. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. Cells 2021;10:3164. [PMID: 34831387 DOI: 10.3390/cells10113164] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Rotondo-Trivette S, Wang B, Gayer C, Parsana R, Luan Y, Sun F, Michail S. Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection. Aliment Pharmacol Ther 2021;54:792-804. [PMID: 34218431 DOI: 10.1111/apt.16496] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Bandali A, Bias TE, Lee DH, Malat G. Duration of Perioperative Antimicrobial Prophylaxis in Orthotopic Liver Transplantation Patients. Prog Transplant 2020;30:265-70. [PMID: 32597322 DOI: 10.1177/1526924820933824] [Reference Citation Analysis]
189 Fuchs BB, Tharmalingam N, Mylonakis E. Vulnerability of long-term care facility residents to Clostridium difficile infection due to microbiome disruptions. Future Microbiol 2018;13:1537-47. [PMID: 30311778 DOI: 10.2217/fmb-2018-0157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
190 Mizusawa M, Small BA, Hsu YJ, Sharara SL, Advic E, Kauffman C, Milstone AM, Feldman L, Pahwa AK, Trivedi JB, Landrum MB, Maragakis LL, Carroll KC, Cosgrove SE, Rock C. Prescriber Behavior in Clostridioides difficile Testing: A 3-Hospital Diagnostic Stewardship Intervention. Clin Infect Dis 2019;69:2019-21. [PMID: 31125399 DOI: 10.1093/cid/ciz295] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
191 Feuerstadt P, Aroniadis OC, Svedlund FL, Garcia M, Stong L, Boules M, Khanna S. Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Dig Dis Sci 2021. [PMID: 34275058 DOI: 10.1007/s10620-021-07141-9] [Reference Citation Analysis]
192 Guh AY, Hatfield KM, Winston LG, Martin B, Johnston H, Brousseau G, Farley MM, Wilson L, Perlmutter R, Phipps EC, Dumyati GK, Nelson D, Hatwar T, Kainer MA, Paulick AL, Karlsson M, Gerding DN, McDonald LC. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates. Clin Infect Dis 2019;69:1667-74. [PMID: 30615074 DOI: 10.1093/cid/ciz009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
193 Luo Y, Lucas AL, Grinspan AM. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection. Dig Dis Sci 2020;65:1125-33. [DOI: 10.1007/s10620-019-05821-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
194 Horns H, Draenert R. [23/f-Recurrent diarrhea : Preparation for the medical specialist examination: part 38]. Internist (Berl) 2021;62:277-81. [PMID: 33760923 DOI: 10.1007/s00108-021-01008-x] [Reference Citation Analysis]
195 Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211017725. [PMID: 34104212 DOI: 10.1177/17562848211017725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Shellito AD, Russell MM. Diverting Loop Ileostomy for Clostridium Difficile Colitis: A Systematic Review and Meta-analysis. Am Surg 2020;86:1269-76. [PMID: 33284670 DOI: 10.1177/0003134820964213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Dbeibo L, Brinkman A, Beeler C, Fadel W, Snyderman W, Hatfield N, Sadowski J, Wang Y, Kelley K, Webb D, Azar J, Kara A. Utilizing a real-time discussion approach to improve the appropriateness of Clostridioides difficile testing and the potential unintended consequences of this strategy. Infect Control Hosp Epidemiol 2020;41:1215-8. [PMID: 32594961 DOI: 10.1017/ice.2020.276] [Reference Citation Analysis]
198 Larrainzar-Coghen T, Rodríguez-Pardo D, Fernández-Hidalgo N, Puig-Asensio M, Pigrau C, Ferrer C, Rodríguez V, Bartolomé R, Campany D, Almirante B. Secular trends in the epidemiology of Clostridium difficile infection (CDI) at a tertiary care hospital in Barcelona, 2006-2015: A prospective observational study. Anaerobe 2018;51:54-60. [PMID: 29655966 DOI: 10.1016/j.anaerobe.2018.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Tabak YP, Srinivasan A, Yu KC, Kurtz SG, Gupta V, Gelone S, Scoble PJ, McDonald LC. Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: Retrospective analysis of 2016-2017 data from US hospitals. Infect Control Hosp Epidemiol 2019;40:1229-35. [PMID: 31522695 DOI: 10.1017/ice.2019.236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
200 Jayatilleke K. Challenges in Implementing Surveillance Tools of High-Income Countries (HICs) in Low Middle Income Countries (LMICs). Curr Treat Options Infect Dis 2020;:1-11. [PMID: 32874140 DOI: 10.1007/s40506-020-00229-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Golubovska I, Vigante D, Malzubris M, Raga L, Isajevs S, Miscuks A. Severe Clostridium difficile infection with extremely high leucocytosis complicated by a concomitant bloodstream infection caused by Klebsiella pneumoniae after osteomyelitis surgery: A case report. Int J Surg Case Rep 2021;78:155-8. [PMID: 33352444 DOI: 10.1016/j.ijscr.2020.12.018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Nagayoshi Y, Yamamoto K, Sato S, Suyama N, Izumikawa T, Izumikawa K, Miyazaki T, Izumikawa K, Yanagihara K, Mukae H. Clinical significance of a positive Clostridioides difficile glutamate dehydrogenase test on the outcomes of hospitalized older patients. Geriatr Gerontol Int 2020;20:1138-44. [PMID: 33098238 DOI: 10.1111/ggi.14054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
203 Bogdanová K, Doubravská L, Vágnerová I, Hricová K, Pudová V, Röderová M, Papajk J, Uvízl R, Langová K, Kolář M. Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia. Life (Basel) 2021;11:1127. [PMID: 34833003 DOI: 10.3390/life11111127] [Reference Citation Analysis]
204 Schall SE, Li P, Whitman TJ, Petfield JL, Tribble DR, Blyth DM. Clostridioides difficile infections complicating combat-injured patients from Iraq and Afghanistan. Infect Control Hosp Epidemiol 2020;41:1100-2. [PMID: 32600498 DOI: 10.1017/ice.2020.299] [Reference Citation Analysis]
205 Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, Abu-Zidan FM, Ansaloni L, Augustin G, Bala M, Ben-Ishay O, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cortese F, Cui Y, Czepiel J, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckmann C, Eiland EH, Forrester JD, Fraga GP, Frossard JL, Fry DE, Galeiras R, Ghnnam W, Gomes CA, Griffiths EA, Guirao X, Ahmed MH, Herzog T, Kim JI, Iqbal T, Isik A, Itani KMF, Labricciosa FM, Lee YY, Juang P, Karamarkovic A, Kim PK, Kluger Y, Leppaniemi A, Lohsiriwat V, Machain GM, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Ordoñez CA, Pagani L, Petrosillo N, Portela F, Rasa K, Rems M, Sakakushev BE, Segovia-Lohse H, Sganga G, Shelat VG, Spigaglia P, Tattevin P, Tranà C, Urbánek L, Ulrych J, Viale P, Baiocchi GL, Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019;14:8. [PMID: 30858872 DOI: 10.1186/s13017-019-0228-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 15.7] [Reference Citation Analysis]
206 Ossorio PN, Zhou Y. Regulating stool for microbiota transplantation. Gut Microbes 2019;10:105-8. [PMID: 30212271 DOI: 10.1080/19490976.2018.1502537] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
207 Sandora TJ, Bryant KK, Cantey JB, Elward AM, Yokoe DS, Bartlett AH. SHEA neonatal intensive care unit (NICU) white paper series: Practical approaches to Clostridioides difficile prevention. Infect Control Hosp Epidemiol 2018;39:1149-53. [PMID: 30160646 DOI: 10.1017/ice.2018.209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
208 Anjewierden S, Han Z, Foster CB, Pant C, Deshpande A. Risk factors for Clostridium difficile infection in pediatric inpatients: A meta-analysis and systematic review. Infect Control Hosp Epidemiol 2019;40:420-6. [DOI: 10.1017/ice.2019.23] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
209 van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, Dekkers OM, Kuijper EJ, Keller JJ, van Prehn J. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00552-8. [PMID: 34655745 DOI: 10.1016/j.cmi.2021.09.026] [Reference Citation Analysis]
210 Mahida YR. New concepts in C. difficile management. Br Med Bull 2019;131:109-18. [PMID: 31583398 DOI: 10.1093/bmb/ldz029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Doll ME, Zhao J, Kang L, Rittmann B, Alvarez M, Fleming M, Cooper K, Stevens MP, Bearman G. Chasing the rate: An interrupted time series analysis of interventions targeting reported hospital onset Clostridioides difficile, 2013-2018. Infect Control Hosp Epidemiol 2020;41:1142-7. [PMID: 32493530 DOI: 10.1017/ice.2020.247] [Reference Citation Analysis]
212 Selle K, Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, Rivera AJ, Montgomery SA, Fortier LC, Barrangou R, Theriot CM, Ousterout DG. In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials. mBio 2020;11:e00019-20. [PMID: 32156803 DOI: 10.1128/mBio.00019-20] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
213 Speri E, Qian Y, Janardhanan J, Masitas C, Lastochkin E, De Benedetti S, Wang M, Schroeder VA, Wolter WR, Oliver AG, Fisher JF, Mobashery S, Chang M. Structure-Activity Relationship for the Picolinamide Antibacterials that Selectively Target Clostridioides difficile. ACS Med Chem Lett 2021;12:991-5. [PMID: 34141083 DOI: 10.1021/acsmedchemlett.1c00135] [Reference Citation Analysis]
214 Bell J, Vatani J, Raad M, Labaran L, Puvanesarajah V, Hassanzadeh H. Clostridium difficile Infection Following Spine Surgery: Incidence, Risk Factors, and Association With Preoperative Antibiotic Use. Spine (Phila Pa 1976) 2020;45:1572-9. [PMID: 32756273 DOI: 10.1097/BRS.0000000000003627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
215 Sauter M, Uhl P, Foerster KI, Mohr I, Höne RT, Merle U, Burhenne J, Haefeli WE. An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. Journal of Pharmaceutical and Biomedical Analysis 2019;174:633-8. [DOI: 10.1016/j.jpba.2019.06.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
216 Cooper CW, Aithinne KAN, Stevenson BS, Black JE, Johnson DL. Comparison and evaluation of a high volume air sampling system for the collection of Clostridioides difficile endospore aerosol in health care environments. Am J Infect Control 2020;48:1354-60. [PMID: 32334002 DOI: 10.1016/j.ajic.2020.04.014] [Reference Citation Analysis]
217 Shin J, Wi YM, Lee YJ. Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea. Epidemiol Infect 2019;147:e289. [PMID: 31607272 DOI: 10.1017/S0950268819001742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
218 Sandlund J, Bartolome A, Almazan A, Tam S, Biscocho S, Abusali S, Bishop JJ, Nolan N, Estis J, Todd J, Young S, Senchyna F, Banaei N. Ultrasensitive Detection of Clostridioides difficile Toxins A and B by Use of Automated Single-Molecule Counting Technology. J Clin Microbiol 2018;56:e00908-18. [PMID: 30158195 DOI: 10.1128/JCM.00908-18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
219 Matera MG, Rogliani P, Ora J, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opin Pharmacother 2018;19:2043-53. [PMID: 30359143 DOI: 10.1080/14656566.2018.1534957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
220 Varma S, Greendyke WG, Li J, Freedberg DE. Class-specific relationship between use of immunosuppressants and risk for community-acquired Clostridioides difficile infection. Clin Infect Dis 2021:ciab567. [PMID: 34156442 DOI: 10.1093/cid/ciab567] [Reference Citation Analysis]
221 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
222 Azimirad M, Krutova M, Yadegar A, Shahrokh S, Olfatifar M, Aghdaei HA, Fawley WN, Wilcox MH, Zali MR. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. Emerg Microbes Infect 2020;9:1432-43. [PMID: 32520657 DOI: 10.1080/22221751.2020.1780949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
223 Mantri N, Patel H, Badipatla KR, Sun H, Shaikh D, Gongati S, Nayudu SK. Clostridioides difficile Infection and Liver Cirrhosis - A Retrospective, Cohort Study. Clin Exp Gastroenterol 2021;14:229-35. [PMID: 34113145 DOI: 10.2147/CEG.S308862] [Reference Citation Analysis]
224 Kociolek LK, Kutty PK, Polgreen PM, Beekmann SE. Healthcare provider diagnostic testing practices for identification of Clostridioides (Clostridium) difficile in children: an Emerging Infections Network survey. Infect Control Hosp Epidemiol 2019;40:276-80. [PMID: 30767829 DOI: 10.1017/ice.2018.347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
225 Cotter JM, Nicholson MR, Kociolek LK. An Infectious Diseases Perspective on Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc 2019;8:580-4. [PMID: 31550348 DOI: 10.1093/jpids/piz062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
226 Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, Gonzalez MD, Jerris RC, Kehl SC, Patel R, Pritt BS, Richter SS, Robinson-Dunn B, Schwartzman JD, Snyder JW, Telford S 3rd, Theel ES, Thomson RB Jr, Weinstein MP, Yao JD. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018;67:e1-e94. [PMID: 29955859 DOI: 10.1093/cid/ciy381] [Cited by in Crossref: 131] [Cited by in F6Publishing: 98] [Article Influence: 43.7] [Reference Citation Analysis]
227 Redding LE, Kelly BJ, Stefanovski D, Lautenbach JK, Tolomeo P, Cressman L, Gruber E, Meily P, Lautenbach E. Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection. Open Forum Infect Dis 2020;7:ofz541. [PMID: 31976354 DOI: 10.1093/ofid/ofz541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
228 Petty LA, Vaughn VM, Flanders SA, Malani AN, Conlon A, Kaye KS, Thyagarajan R, Osterholzer D, Nielsen D, Eschenauer GA, Bloemers S, McLaughlin E, Gandhi TN. Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients. JAMA Intern Med 2019;179:1519-27. [PMID: 31449295 DOI: 10.1001/jamainternmed.2019.2871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
229 Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, Deptuła A, Agodi A, Nuvials X, Pituch H, Wójcik-Bugajska M, Filipczak-Bryniarska I, Brzozowski B, Krzanowski M, Konturek K, Fedewicz M, Michalak M, Monpierre L, Vanhems P, Gouliouris T, Jurczyszyn A, Goldman-Mazur S, Wultańska D, Kuijper EJ, Skupień J, Biesiada G, Garlicki A. Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics (Basel) 2021;10:299. [PMID: 33805755 DOI: 10.3390/antibiotics10030299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
230 Haifer C, Kelly CR, Paramsothy S, Andresen D, Papanicolas LE, McKew GL, Borody TJ, Kamm M, Costello SP, Andrews JM, Begun J, Chan HT, Connor S, Ghaly S, Johnson PD, Lemberg DA, Paramsothy R, Redmond A, Sheorey H, van der Poorten D, Leong RW. Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut 2020;69:801-10. [PMID: 32047093 DOI: 10.1136/gutjnl-2019-320260] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
231 J Burton S, Hachem C, Abraham JM. Luminal Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 2021;23:4. [PMID: 33758994 DOI: 10.1007/s11894-021-00806-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Baunwall SMD, Terveer EM, Dahlerup JF, Erikstrup C, Arkkila P, Vehreschild MJ, Ianiro G, Gasbarrini A, Sokol H, Kump PK, Satokari R, De Looze D, Vermeire S, Nakov R, Brezina J, Helms M, Kjeldsen J, Rode AA, Kousgaard SJ, Alric L, Trang-Poisson C, Scanzi J, Link A, Stallmach A, Kupcinskas J, Johnsen PH, Garborg K, Rodríguez ES, Serrander L, Brummer RJ, Galpérine KT, Goldenberg SD, Mullish BH, Williams HR, Iqbal TH, Ponsioen C, Kuijper EJ, Cammarota G, Keller JJ, Hvas CL. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Reg Health Eur 2021;9:100181. [PMID: 34693388 DOI: 10.1016/j.lanepe.2021.100181] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
233 Brechmann T, Günther K, Neid M, Schmiegel W, Tannapfel A. Triggers of histologically suspected drug-induced colitis. World J Gastroenterol 2019; 25(8): 967-979 [PMID: 30833802 DOI: 10.3748/wjg.v25.i8.967] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
234 Gonzales-luna AJ, Carlson TJ. Follow your Gut: Microbiome-Based Approaches in the Developmental Pipeline for the Prevention and Adjunctive Treatment of Clostridioides difficile Infection (CDI). Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00729-8] [Reference Citation Analysis]
235 Rubin ZA, Martin EM, Allyn P. Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools. Curr Infect Dis Rep 2018;20:32. [PMID: 29959605 DOI: 10.1007/s11908-018-0639-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
236 Šuljagić V, Milenković B, Perić A, Jovanović D, Begović-Kuprešanin V, Starčević S, Tomić A, Vezmar Kovačević S, Dragojević-Simić V. Healthcare associated Clostridioides difficile infection in adult surgical and medical patients hospitalized in tertiary hospital in Belgrade, Serbia: a seven years prospective cohort study. Libyan J Med 2020;15:1708639. [PMID: 31905110 DOI: 10.1080/19932820.2019.1708639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
237 Shen Y, Ellison J, Leal J, Bush KR, Chandran AU, Fathima S, Conly JM. The use of laboratory-identified event surveillance to classify adverse outcomes due to Clostridioides difficile infection in Canadian long-term care facilities. Infect Control Hosp Epidemiol 2021;42:557-64. [PMID: 33222722 DOI: 10.1017/ice.2020.1269] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
238 Marcelin JR, Brewer C, Beachy M, Lyden E, Winterboer T, Murphy CN, Fey PD, Hood L, Van Schooneveld TC. Hardwiring diagnostic stewardship using electronic ordering restrictions for gastrointestinal pathogen testing. Infect Control Hosp Epidemiol 2019;40:668-73. [PMID: 31012405 DOI: 10.1017/ice.2019.78] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
239 Banz A, Lantz A, Riou B, Foussadier A, Miller M, Davies K, Wilcox M. Sensitivity of Single-Molecule Array Assays for Detection of Clostridium difficile Toxins in Comparison to Conventional Laboratory Testing Algorithms. J Clin Microbiol 2018;56:e00452-18. [PMID: 29898996 DOI: 10.1128/JCM.00452-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
240 Wu X, Shen WJ, Deshpande A, Olaitan AO, Palmer KL, Garey KW, Hurdle JG. The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests. J Clin Microbiol 2021;59:e0058521. [PMID: 34132582 DOI: 10.1128/JCM.00585-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Kortt NC, Santhakumar C, Davis RJ, Strasser SI, McCaughan GW, Liu K, Majumdar A. Prevalence and outcomes of Clostridioides difficile infection in liver transplant recipients. Transpl Infect Dis 2021;:e13758. [PMID: 34762768 DOI: 10.1111/tid.13758] [Reference Citation Analysis]
242 Antonelli M, Martin-Loeches I, Dimopoulos G, Gasbarrini A, Vallecoccia MS. Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement. Intensive Care Med 2020;46:215-24. [PMID: 31938827 DOI: 10.1007/s00134-019-05873-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
243 Chang LJ, Hsiao CJ, Chen B, Liu TY, Ding J, Hsu WT, Su-Ortiz V, Chen ST, Su KY, Wu HP, Lee CC. Accuracy and comparison of two rapid multiplex PCR tests for gastroenteritis pathogens: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2021;8. [PMID: 33648983 DOI: 10.1136/bmjgast-2020-000553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
244 Landry ML, Topal JE, Estis J, Katzenbach P, Nolan N, Sandlund J. High Agreement Between an Ultrasensitive Clostridioides difficile Toxin Assay and a C. difficile Laboratory Algorithm Utilizing GDH-and-Toxin Enzyme Immunoassays and Cytotoxin Testing. J Clin Microbiol 2020;58:e01629-19. [PMID: 31776192 DOI: 10.1128/JCM.01629-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Xiao Y, Angulo MT, Lao S, Weiss ST, Liu YY. An ecological framework to understand the efficacy of fecal microbiota transplantation. Nat Commun 2020;11:3329. [PMID: 32620839 DOI: 10.1038/s41467-020-17180-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
246 Fatima R, Aziz M. The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview. Cureus 2019;11:e3977. [PMID: 30967977 DOI: 10.7759/cureus.3977] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
247 Uchiyama AAT, Lopes MSM, Vana MNM, Peixoto RD. Clostridium difficile Infection Leading to Intestinal Pneumatosis in a Patient with a Recent Diagnosis of Pancreatic Cancer Local Recurrence: A Case Report and Literature Review. Case Rep Oncol 2021;14:1111-7. [PMID: 34413741 DOI: 10.1159/000513003] [Reference Citation Analysis]
248 Burmeister AR, Hansen E, Cunningham JJ, Rego EH, Turner PE, Weitz JS, Hochberg ME. Fighting microbial pathogens by integrating host ecosystem interactions and evolution. Bioessays 2021;43:e2000272. [PMID: 33377530 DOI: 10.1002/bies.202000272] [Reference Citation Analysis]
249 Abutaleb NS, Seleem MN. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Sci Rep 2020;10:7701. [PMID: 32382070 DOI: 10.1038/s41598-020-64882-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
250 Hooker EA, Mallow PJ, McKinney C, Gnoni ML, Fernandez Gonzales F. Use of a Launderable Bed Barrier and Antibiotic Stewardship to Decrease Hospital Onset Clostridioides difficile Infections in an Acute Care Hospital: A Retrospective Pre-Post Case Study. J Health Econ Outcomes Res 2019;6:196-202. [PMID: 32685591 DOI: 10.36469/001c.11149] [Reference Citation Analysis]
251 Dutta D, Jafri F, Stuhr D, Knoll BM, Lim SH. A contemporary review of Clostridioides difficile infections in patients with haematologic diseases. J Intern Med 2021;289:293-308. [PMID: 32910532 DOI: 10.1111/joim.13173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
252 Gentry CA, Williams RJ 2nd, Campbell D. Continued decline in the prevalence of the Clostridioides difficile BI/NAP1/027 strain across the United States Veterans Health Administration. Diagn Microbiol Infect Dis 2021;100:115308. [PMID: 33626478 DOI: 10.1016/j.diagmicrobio.2021.115308] [Reference Citation Analysis]
253 Heinzinger LR, Johnson A, Wurster JI, Nilson R, Penumutchu S, Belenky P. Oxygen and Metabolism: Digesting Determinants of Antibiotic Susceptibility in the Gut. iScience 2020;23:101875. [PMID: 33354661 DOI: 10.1016/j.isci.2020.101875] [Reference Citation Analysis]
254 Olesen SW, Panchal P, Chen J, Budree S, Osman M. Global disparities in faecal microbiota transplantation research. The Lancet Gastroenterology & Hepatology 2020;5:241. [DOI: 10.1016/s2468-1253(19)30452-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
255 Ghani R, Mullish BH, McDonald JAK, Ghazy A, Williams HRT, Brannigan ET, Mookerjee S, Satta G, Gilchrist M, Duncan N, Corbett R, Innes AJ, Pavlů J, Thursz MR, Davies F, Marchesi JR. Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. Clin Infect Dis 2021;72:1444-7. [PMID: 32681643 DOI: 10.1093/cid/ciaa948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
256 Gerardin Y, Timberlake S, Allegretti JR, Smith MB, Kassam Z. Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome. J Infect Dis 2021;223:S276-82. [PMID: 33330910 DOI: 10.1093/infdis/jiaa700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Perry DA, Shirley D, Micic D, Patel CP, Putler R, Menon A, Young VB, Rao K. External Validation and Comparison of Clostridioides difficile Severity Scoring Systems. Clin Infect Dis 2021:ciab737. [PMID: 34459885 DOI: 10.1093/cid/ciab737] [Reference Citation Analysis]
258 Alrawashdeh M, Rhee C, Hsu H, Wang R, Horan K, Lee GM. Assessment of Federal Value-Based Incentive Programs and In-Hospital Clostridioides difficile Infection Rates. JAMA Netw Open 2021;4:e2132114. [PMID: 34714336 DOI: 10.1001/jamanetworkopen.2021.32114] [Reference Citation Analysis]
259 Lei DK, Ollech JE, Andersen M, Weisshof R, Zmeter N, Sossenheimer P, Rubin DT. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol 2019;114:1904-8. [PMID: 31714359 DOI: 10.14309/ajg.0000000000000460] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
260 Menon A, Perry DA, Motyka J, Weiner S, Standke A, Penkevich A, Keidan M, Young VB, Rao K. Changes in the Association between Diagnostic Testing Method, PCR Ribotype, and Clinical Outcomes from Clostridioides difficile Infection: One Institution's Experience. Clin Infect Dis 2020:ciaa1395. [PMID: 32930705 DOI: 10.1093/cid/ciaa1395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
261 Tilton CS, Sexton M, Johnson SW, Gu C, Chen Z, Robichaux C, Metzger NL. Evaluation of a risk assessment model to predict infection with healthcare facility-onset Clostridioides difficile. Am J Health Syst Pharm 2021:zxab201. [PMID: 33954428 DOI: 10.1093/ajhp/zxab201] [Reference Citation Analysis]
262 Budi N, Godfrey JJ, Safdar N, Shukla SK, Rose WE. Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Clostridioides difficile. Antimicrob Agents Chemother 2021:AAC. [PMID: 33649111 DOI: 10.1128/AAC.01431-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34453142 DOI: 10.1038/s41575-021-00499-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Ressler A, Wang J, Rao K. Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211048127. [PMID: 34646358 DOI: 10.1177/17562848211048127] [Reference Citation Analysis]
265 Chai J, Lee CH. Management of Primary and Recurrent Clostridium difficile Infection: An Update. Antibiotics (Basel) 2018;7:E54. [PMID: 29966323 DOI: 10.3390/antibiotics7030054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
266 Gill M, Blacketer C, Chitti F, Telfer K, Papanicolas L, Dann LM, Tucker EC, Bryant RV, Costello SP. Physician and patient perceptions of fecal microbiota transplant for recurrent or refractory Clostridioides difficile in the first 6 years of a central stool bank. JGH Open 2020;4:950-7. [PMID: 33102769 DOI: 10.1002/jgh3.12396] [Reference Citation Analysis]
267 Alrahmany D, Ereshefsky BJ, El Nekidy WS, Harb G, Pontiggia L, Ghazi IM. Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients. J Infect Public Health 2021;14:1642-9. [PMID: 34627059 DOI: 10.1016/j.jiph.2021.09.016] [Reference Citation Analysis]
268 Tariq R, Laguio-Vila M, Tahir MW, Orenstein R, Pardi DS, Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994046. [PMID: 33747124 DOI: 10.1177/1756284821994046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
269 de Jager P, Smith O, Bolon S, Thomas J, Richards GA. Epidemiology of Clostridioides difficile in South Africa. PLoS One 2021;16:e0259771. [PMID: 34813626 DOI: 10.1371/journal.pone.0259771] [Reference Citation Analysis]
270 Seo SK, Liu C, Dadwal SS. Infectious Disease Complications in Patients with Cancer. Crit Care Clin 2021;37:69-84. [PMID: 33190776 DOI: 10.1016/j.ccc.2020.09.001] [Reference Citation Analysis]
271 Huang GQ, Bai Y, Sun ZQ, Liu J. Successful Treatment of Pseudomembranous Colitis with Fecal Microbiota Transplantation - A Case Study on A Patient Rescued by Extracorporeal Cardiopulmonary Resuscitation After Cardiac Arrest. Ann Transplant 2020;25:e923283. [PMID: 32657282 DOI: 10.12659/AOT.923283] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
272 Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol 2021;19:77-94. [PMID: 32968241 DOI: 10.1038/s41579-020-0438-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 55] [Article Influence: 22.5] [Reference Citation Analysis]
273 Reygner J, Charrueau C, Delannoy J, Mayeur C, Robert V, Cuinat C, Meylheuc T, Mauras A, Augustin J, Nicolis I, Modoux M, Joly F, Waligora-Dupriet AJ, Thomas M, Kapel N. Freeze-dried fecal samples are biologically active after long-lasting storage and suited to fecal microbiota transplantation in a preclinical murine model of Clostridioides difficile infection. Gut Microbes 2020;11:1405-22. [PMID: 32501140 DOI: 10.1080/19490976.2020.1759489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
274 Zhu Y, Mei Q, Fu Y, Zeng Y. Alteration of gut microbiota in acute pancreatitis and associated therapeutic strategies. Biomed Pharmacother 2021;141:111850. [PMID: 34214727 DOI: 10.1016/j.biopha.2021.111850] [Reference Citation Analysis]
275 Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, Hvas CL. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 2020;29-30:100642. [PMID: 33437951 DOI: 10.1016/j.eclinm.2020.100642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
276 Schultz K, Sickbert-Bennett E, Marx A, Weber DJ, DiBiase LM, Campbell-Bright S, Bode LE, Baker M, Belhorn T, Buchanan M, Goldbach S, Harden J, Hoke E, Huenniger B, Juliano JJ, Langston M, Ritchie H, Rutala WA, Smith J, Summerlin-Long S, Teal L, Gilligan P. Preventable Patient Harm: a Multidisciplinary, Bundled Approach to Reducing Clostridium difficile Infections While Using a Glutamate Dehydrogenase/Toxin Immunochromatographic Assay/Nucleic Acid Amplification Test Diagnostic Algorithm. J Clin Microbiol 2018;56:e00625-18. [PMID: 29997201 DOI: 10.1128/JCM.00625-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
277 Marzullo P, Di Renzo L, Pugliese G, De Siena M, Barrea L, Muscogiuri G, Colao A, Savastano S; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group. From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. Int J Obes Suppl 2020;10:35-49. [PMID: 32714511 DOI: 10.1038/s41367-020-0017-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
278 Wang EW, Weekley A, McCarty J, Koo H, Lembcke B, Al Mohajer M. Impact of a division-wide bundle on hospital-acquired Clostridioides difficile cases, antibiotic days of therapy, testing appropriateness, and associated financial costs. Avicenna J Med 2021;11:27-32. [PMID: 33520786 DOI: 10.4103/ajm.ajm_193_19] [Reference Citation Analysis]
279 D'Silva KM, Mehta R, Mitchell M, Lee TC, Singhal V, Wilson MG, McDonald EG. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clin Microbiol Infect 2021:S1198-743X(21)00035-5. [PMID: 33465501 DOI: 10.1016/j.cmi.2021.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
280 Intra J, Carcione D, Sarto C, Brambilla P. A significant decreased in the frequency of Clostridioides difficile infection at the Italian Hospital of Desio over the last decade. Anaerobe 2021;70:102376. [PMID: 33901657 DOI: 10.1016/j.anaerobe.2021.102376] [Reference Citation Analysis]
281 Gupta S, Zhu J, McCarty TR, Pruce J, Kassam Z, Kelly C, Fischer M, Allegretti JR. Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection. J Gastroenterol Hepatol 2021. [PMID: 33682170 DOI: 10.1111/jgh.15483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Hetem DJ, Bos-Sanders I, Nijhuis RHT, Tamminga S, Berlinger L, Kuijper EJ, Sickler JJ, Claas ECJ. Evaluation of the Liat Cdiff Assay for Direct Detection of Clostridioides difficile Toxin Genes within 20 Minutes. J Clin Microbiol 2019;57:e00416-19. [PMID: 30944191 DOI: 10.1128/JCM.00416-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Dembrovszky F, Gede N, Szakács Z, Hegyi P, Kiss S, Farkas N, Molnár Z, Imrei M, Dohos D, Péterfi Z. Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis. Infect Dis Ther 2021;10:201-11. [PMID: 33106983 DOI: 10.1007/s40121-020-00356-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
284 Hassan S, Ng VL, Aqul A. It takes a village: primary care of the pediatric liver transplant recipient. Curr Opin Pediatr 2019;31:636-44. [PMID: 31369476 DOI: 10.1097/MOP.0000000000000809] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
285 Wolf J, Kalocsai K, Fortuny C, Lazar S, Bosis S, Korczowski B, Petit A, Bradford D, Croos-Dabrera R, Incera E, Melis J, van Maanen R. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Clin Infect Dis 2020;71:2581-8. [PMID: 31773143 DOI: 10.1093/cid/ciz1149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
286 Zhang K, Beckett P, Abouanaser S, Stankus V, Lee C, Smieja M. Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection. BMC Infect Dis 2019;19:51. [PMID: 30642269 DOI: 10.1186/s12879-019-3676-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
287 Hiraki M, Suzuki R, Tanaka N, Fukunaga H, Kinoshita Y, Kimura H, Tsutsui S, Murata M, Morita S. Community-acquired fulminant Clostridioides (Clostridium) difficile infection by ribotype 027 isolate in Japan: a case report. Surg Case Rep 2021;7:137. [PMID: 34101061 DOI: 10.1186/s40792-021-01220-9] [Reference Citation Analysis]
288 Alagna L, Palomba E, Mangioni D, Bozzi G, Lombardi A, Ungaro R, Castelli V, Prati D, Vecchi M, Muscatello A, Bandera A, Gori A. Multidrug-Resistant Gram-Negative Bacteria Decolonization in Immunocompromised Patients: A Focus on Fecal Microbiota Transplantation. Int J Mol Sci 2020;21:E5619. [PMID: 32764526 DOI: 10.3390/ijms21165619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
289 Gibson CM, Childs‐kean LM, Naziruddin Z, Howell CK. The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation. Transpl Infect Dis 2021;23. [DOI: 10.1111/tid.13397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
290 Ancona G, Alagna L, Lombardi A, Palomba E, Castelli V, Renisi G, Dondossola D, Iavarone M, Muscatello A, Gori A, Bandera A. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. Infect Immun 2021;89:e0037621. [PMID: 34460287 DOI: 10.1128/IAI.00376-21] [Reference Citation Analysis]
291 Shen J, Mehrotra DV, Dorr MB, Zeng Z, Li J, Xu X, Nickle D, Holzinger ER, Chhibber A, Wilcox MH, Blanchard RL, Shaw PM. Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment. mSphere 2020;5:e00232-20. [PMID: 32376702 DOI: 10.1128/mSphere.00232-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
292 Noor A, Krilov LR. Clostridium difficile Infection in Children. Pediatr Ann 2018;47:e359-65. [PMID: 30208195 DOI: 10.3928/19382359-20180803-01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
293 Savage TJ, Sandora TJ. Clostridioides difficile Infection in Children: The Role of Infection Prevention and Antimicrobial Stewardship. J Pediatric Infect Dis Soc 2021;10:S64-8. [PMID: 34791402 DOI: 10.1093/jpids/piab052] [Reference Citation Analysis]
294 Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, Valencia Alijo A, Díaz-Pollán B, Rodríguez Hernández MJ, Merino De Lucas E, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez Gutiérrez B, Rodríguez-Pardo D, Ramos Martínez A, De La Torre Cisneros J, López-Medrano F, Cobo Reinoso J. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. J Clin Med 2020;10:E2. [PMID: 33374989 DOI: 10.3390/jcm10010002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
295 Berland M, Cadiou J, Levenez F, Galleron N, Quinquis B, Thirion F, Gauthier F, Le Chatelier E, Plaza Oñate F, Schwintner C, Rabot S, Lepage P, Ehrlich D, Doré J, Juste C. High engraftment capacity of frozen ready-to-use human fecal microbiota transplants assessed in germ-free mice. Sci Rep 2021;11:4365. [PMID: 33623056 DOI: 10.1038/s41598-021-83638-7] [Reference Citation Analysis]
296 Wu T, Davis SL, Church B, Alangaden GJ, Kenney RM. Outcomes of clinical decision support for outpatient management of Clostridioides difficile infection. Infect Control Hosp Epidemiol 2021;:1-4. [PMID: 34583800 DOI: 10.1017/ice.2021.397] [Reference Citation Analysis]
297 Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S, Wultańska D, Garlicki A, Biesiada G. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019;38:1211-21. [PMID: 30945014 DOI: 10.1007/s10096-019-03539-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 29.0] [Reference Citation Analysis]
298 Shoaei P, Shojaei H, Jalali M, Khorvash F, Hosseini SM, Ataei B, Vakili B, Ebrahimi F, Tavakoli H, Esfandiari Z, Weese JS. Clostridium difficile isolated from faecal samples in patients with ulcerative colitis. BMC Infect Dis 2019;19:361. [PMID: 31039738 DOI: 10.1186/s12879-019-3965-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
299 Wadskier F, Cowman K, Szymczak WA, Weston G, Guo Y, Bartash R, Levi MH, Nori P. Diagnostic stewardship of Clostridioides difficile polymerase chain reaction results from syndromic diarrhea panel and implications for patient outcomes. Diagn Microbiol Infect Dis 2020;97:115032. [PMID: 32299633 DOI: 10.1016/j.diagmicrobio.2020.115032] [Reference Citation Analysis]
300 Weller BM, Shaddix BP, Oschman A, Johnson PN, Neely SB, Chaaban H, Williams PK, Miller J. A Pilot Evaluation of the Possible Association of Metronidazole With Neurodevelopmental Outcomes in Premature Neonates. J Pediatr Pharmacol Ther 2021;26:455-9. [PMID: 34239396 DOI: 10.5863/1551-6776-26.5.455] [Reference Citation Analysis]
301 de Jonge SW, Boldingh QJJ, Solomkin JS, Dellinger EP, Egger M, Salanti G, Allegranzi B, Boermeester MA. Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis. Lancet Infect Dis 2020;20:1182-92. [PMID: 32470329 DOI: 10.1016/S1473-3099(20)30084-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
302 Păduraru DN, Ion D, Dumitrașcu MC, Petca R, Petca A, Șandru F, Andronic O, Radu G, Bolocan A. Clostridium difficile infection characteristics in a general surgery clinic. Exp Ther Med 2021;22:1112. [PMID: 34504566 DOI: 10.3892/etm.2021.10546] [Reference Citation Analysis]
303 Enoch DA, Santos R, Phillips CJ, Micallef C, Murphy ME, Aliyu SH, Massey D, Brown NM. Real-world use of fidaxomicin in a large UK tertiary hospital: how effective is it for treating recurrent disease? J Hosp Infect 2018;100:142-6. [PMID: 29746874 DOI: 10.1016/j.jhin.2018.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
304 Bishop PA, Isache C, McCarter YS, Smotherman C, Gautam S, Jankowski CA. Clinical impact of a pharmacist-led antimicrobial stewardship initiative evaluating patients with Clostridioides difficile colitis. J Investig Med 2020;68:888-92. [PMID: 32066570 DOI: 10.1136/jim-2019-001173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
305 Cammarota G, Gallo A, Bibbò S. Fecal microbiota transplant for C. difficile infection: Just say yes. Anaerobe 2019;60:102109. [PMID: 31644957 DOI: 10.1016/j.anaerobe.2019.102109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
306 Barker AK, Cowley ES, McKinley L, Wright MO, Safdar N. An in-room observation study of hand hygiene and contact precaution compliance for Clostridioides difficile patients. Am J Infect Control 2019;47:1273-6. [PMID: 31060870 DOI: 10.1016/j.ajic.2019.03.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
307 Alashmali S. Diarrhea/Constipation. In: Aljaaly EA, Khalifa NA, Naaman RK, Bakhsh MA, editors. Cases on Medical Nutrition Therapy for Gastrointestinal Disorders. IGI Global; 2021. pp. 69-92. [DOI: 10.4018/978-1-7998-3802-9.ch004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
308 Stevens VW, Shoemaker HE, Jones MM, Jones BE, Nelson RE, Khader K, Samore MH, Rubin MA. Validation of the SHEA/IDSA severity criteria to predict poor outcomes among inpatients and outpatients with Clostridioides difficile infection. Infect Control Hosp Epidemiol 2020;41:510-6. [PMID: 31996280 DOI: 10.1017/ice.2020.8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
309 Maestri AC, Raboni SM, Cogo LL, Rossi MV, Nogueira KS. Standardisation and validation of an in-house quantitative real-time polymerase chain reaction (qPCR) assay for the diagnosis of Clostridioides difficile infection. J Microbiol Methods 2021;193:106399. [PMID: 34958834 DOI: 10.1016/j.mimet.2021.106399] [Reference Citation Analysis]
310 Wickramage I, Spigaglia P, Sun X. Mechanisms of antibiotic resistance of Clostridioides difficile. J Antimicrob Chemother 2021:dkab231. [PMID: 34297842 DOI: 10.1093/jac/dkab231] [Reference Citation Analysis]
311 Mayer EF, Maron G, Dallas RH, Ferrolino J, Tang L, Sun Y, Danziger-Isakov L, Paulsen GC, Fisher BT, Vora SB, Englund J, Steinbach WJ, Michaels M, Green M, Yeganeh N, Gibson JE, Dominguez SR, Nicholson MR, Dulek DE, Ardura MI, Rajan S, Gonzalez BE, Beneri C, Herold BC. A multicenter study to define the epidemiology and outcomes of Clostridioides difficile infection in pediatric hematopoietic cell and solid organ transplant recipients. Am J Transplant 2020;20:2133-42. [PMID: 32064754 DOI: 10.1111/ajt.15826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Michener A, Heath B, Crnich CJ, Moehring R, Schmader K, Mody L, Branch-Elliman W, Jump RLP. Infections in Older Adults: A Case-Based Discussion Series Emphasizing Antibiotic Stewardship. MedEdPORTAL 2018;14:10754. [PMID: 30800954 DOI: 10.15766/mep_2374-8265.10754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
313 Heleno CT, Tagintsev A, Lasley K, Summerfield D. Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection. Cureus 2021;13:e16559. [PMID: 34327111 DOI: 10.7759/cureus.16559] [Reference Citation Analysis]
314 Bodily-Bartrum M, Adeyeye AA. Journal club: "Impact of a C. difficile infection (CDI) reduction bundle and its components on CDI diagnosis and prevention". Am J Infect Control 2021;49:403-4. [PMID: 33640110 DOI: 10.1016/j.ajic.2020.12.015] [Reference Citation Analysis]
315 Gite S, Archambault D, Cappillino MP, Cunha D, Dorich V, Shatova T, Tempesta A, Walsh B, Walsh JA, Williams A, Kirby JE, Bowers J, Straus D. A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples. Sci Rep 2018;8:8364. [PMID: 29849171 DOI: 10.1038/s41598-018-26353-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
316 Misch EA, Safdar N. Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population. Infect Dis Clin North Am 2019;33:447-66. [PMID: 31005136 DOI: 10.1016/j.idc.2019.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
317 Minotti C, Barbieri E, Giaquinto C, Donà D. Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles. Pathogens 2021;10:1343. [PMID: 34684291 DOI: 10.3390/pathogens10101343] [Reference Citation Analysis]
318 Popa D, Neamtu B, Mihalache M, Boicean A, Banciu A, Banciu DD, Moga DFC, Birlutiu V. Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI? J Clin Med 2021;10:5822. [PMID: 34945118 DOI: 10.3390/jcm10245822] [Reference Citation Analysis]
319 Abukhalil AD, AbuKhdeir L, Hamed M, Al Shami N, Naseef HA, Aiesh BM, Sabateen A. Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine. Infect Drug Resist 2021;14:4681-8. [PMID: 34785915 DOI: 10.2147/IDR.S333985] [Reference Citation Analysis]
320 Kumar V, Fischer M. Expert opinion on fecal microbiota transplantation for the treatment of Clostridioides difficile infection and beyond. Expert Opin Biol Ther. 2020;20:73-81. [PMID: 31690143 DOI: 10.1080/14712598.2020.1689952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
321 Shin D, Rahimi H, Haroon S, Merritt A, Vemula A, Noronha A, Lebedis CA. Imaging of Gastrointestinal Tract Perforation. Radiologic Clinics of North America 2020;58:19-44. [DOI: 10.1016/j.rcl.2019.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
322 Remes-Troche JM. A never-ending story. Clostridioides difficile, one more postoperative factor to look out for. Rev Gastroenterol Mex (Engl Ed) 2020;85:225-6. [PMID: 32111346 DOI: 10.1016/j.rgmx.2019.11.005] [Reference Citation Analysis]
323 Crothers JW, Chu ND, Nguyen LTT, Phillips M, Collins C, Fortner K, Del Rio-Guerra R, Lavoie B, Callas P, Velez M, Cohn A, Elliott RJ, Wong WF, Vo E, Wilcox R, Smith M, Kassam Z, Budd R, Alm EJ, Mawe GM, Moses PL. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterol 2021;21:281. [PMID: 34238227 DOI: 10.1186/s12876-021-01856-9] [Reference Citation Analysis]
324 Musuuza JS, Hundt AS, Carayon P, Christensen K, Ngam C, Haun N, Safdar N. Implementation of a Clostridioides difficile prevention bundle: Understanding common, unique, and conflicting work system barriers and facilitators for subprocess design. Infect Control Hosp Epidemiol 2019;40:880-8. [PMID: 31190669 DOI: 10.1017/ice.2019.150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Zacharioudakis IM, Zervou FN, Shehadeh F, Mylona EK, Mylonakis E. Association of Community Factors with Hospital-onset Clostridioides (Clostridium) difficile Infection: A Population Based U.S.-wide Study. EClinicalMedicine 2019;8:12-9. [PMID: 31193719 DOI: 10.1016/j.eclinm.2019.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
326 Jiang M, Leung NH, Ip M, You JHS. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection. PLoS One. 2018;13:e0201539. [PMID: 30048534 DOI: 10.1371/journal.pone.0201539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
327 Chen J, Zaman A, Ramakrishna B, Olesen SW. Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank. Front Cell Infect Microbiol 2021;11:622949. [PMID: 33937092 DOI: 10.3389/fcimb.2021.622949] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
328 Ferrari L, Fichera A. Clostridioides Difficile Infection. Dis Colon Rectum 2021;64:151-5. [PMID: 33315710 DOI: 10.1097/DCR.0000000000001900] [Reference Citation Analysis]
329 Hitchcock MM, Holubar M, Hogan CA, Tompkins LS, Banaei N. Dual Reporting of Clostridioides difficile PCR and Predicted Toxin Result Based on PCR Cycle Threshold Reduces Treatment of Toxin-Negative Patients without Increases in Adverse Outcomes. J Clin Microbiol 2019;57:e01288-19. [PMID: 31511334 DOI: 10.1128/JCM.01288-19] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
330 Mawer D, Byrne F, Drake S, Brown C, Prescott A, Warne B, Bousfield R, Skittrall J, Ramsay I, Somasunderam D, Bevan M, Coslett J, Rao J, Stanley P, Kennedy A, Dobson R, Long S, Obisanya T, Esmailji T, Petridou C, Saeed K, Brechany K, Davis-blue K, O'horan H, Wake B, Martin J, Featherstone J, Hall C, Allen J, Johnson G, Hornigold C, Amir N, Henderson K, Mcclements C, Liew I, Deshpande A, Vink E, Trigg D, Guilfoyle J, Scarborough M, Scarborough C, Wong T, Walker T, Fawcett N, Morris G, Tomlin K, Grix C, O'cofaigh E, Mccaffrey D, Cooper M, Corbett K, French K, Harper S, Hayward C, Reid M, Whatley V, Winfield J, Hoque S, Kelly L, King I, Bradley A, Mccullagh B, Hibberd C, Merron M, Mccabe C, Horridge S, Taylor J, Koo S, Elsanousi F, Saunders R, Lim F, Bond A, Stone S, Milligan I, Mack D, Nagar A, West R, Wilcox M, Kirby A, Sandoe J. Cross-sectional study of the prevalence, causes and management of hospital-onset diarrhoea. Journal of Hospital Infection 2019;103:200-9. [DOI: 10.1016/j.jhin.2019.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
331 Guery B, Galperine T, Barbut F. Clostridioides difficile: diagnosis and treatments. BMJ. 2019;366:l4609. [PMID: 31431428 DOI: 10.1136/bmj.l4609] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
332 Ser HL, Letchumanan V, Goh BH, Wong SH, Lee LH. The Use of Fecal Microbiome Transplant in Treating Human Diseases: Too Early for Poop? Front Microbiol 2021;12:519836. [PMID: 34054740 DOI: 10.3389/fmicb.2021.519836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
333 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
334 Marra AR, Alzunitan M, Abosi O, Edmond MB, Street WN, Cromwell JW, Salinas JL. Modest Clostridiodes difficile infection prediction using machine learning models in a tertiary care hospital. Diagn Microbiol Infect Dis 2020;98:115104. [PMID: 32650284 DOI: 10.1016/j.diagmicrobio.2020.115104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Chowdhry M, Haden D, Kemper S, Helmick K, Kawsara M, Huggett A, Stark A, Khan A, Shah M, Bhaty M, Farooq J, Singh S, McJunkin B. Usual opioid dosing does not adversely affect the course of healthcare-associated Clostridioides difficile infection. Pain Manag 2021;11:151-7. [PMID: 33350354 DOI: 10.2217/pmt-2020-0066] [Reference Citation Analysis]
336 Alfayyadh M, Collins DA, Tempone S, McCann R, Armstrong PK, Riley TV, Cook A. Recurrence of Clostridium difficile infection in the Western Australian population. Epidemiol Infect 2019;147:e153. [PMID: 31063109 DOI: 10.1017/S0950268819000499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
337 Abu-Sbeih H, Ali FS, Wang Y. Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients. Curr Gastroenterol Rep 2019;21:8. [PMID: 30815766 DOI: 10.1007/s11894-019-0677-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
338 L'Huillier AG, Ferreira VH, Ku T, Bahinskaya I, Kumar D, Humar A. Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients. Am J Transplant 2019;19:2495-504. [PMID: 30916879 DOI: 10.1111/ajt.15371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
339 Weng MK, Adkins SH, Bamberg W, Farley MM, Espinosa CC, Wilson L, Perlmutter R, Holzbauer S, Whitten T, Phipps EC, Hancock EB, Dumyati G, Nelson DS, Beldavs ZG, Ocampo V, Davis CM, Rue B, Korhonen L, McDonald LC, Guh AY. Risk factors for community-associated Clostridioides difficile infection in young children. Epidemiol Infect 2019;147:e172. [PMID: 31063097 DOI: 10.1017/S0950268819000372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 Guery B. Clostridium difficile infection trials: what is the primary endpoint? Lancet Infect Dis 2019;19:219-20. [PMID: 30709664 DOI: 10.1016/S1473-3099(18)30626-1] [Reference Citation Analysis]
341 Jachowicz E, Pobiega M, Różańska A, Wójkowska-mach J. Growing consumption of antibiotics and epidemiology of Clostridioides difficile infections in Poland: A need to develop new solutions. AMicr 2019. [DOI: 10.1556/030.66.2019.024] [Reference Citation Analysis]
342 Hassoun A. Clostridium difficile associated disease. BMJ 2018;363:k4369. [PMID: 30373736 DOI: 10.1136/bmj.k4369] [Reference Citation Analysis]
343 Rinaldi A, Reed EE, Stevenson KB, Coe K, Smith JM. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile. J Clin Pharm Ther 2021;46:993-8. [PMID: 33609052 DOI: 10.1111/jcpt.13387] [Reference Citation Analysis]
344 Song Y, Shao HY, Cheng X, Guo Y. First case of periprosthetic joint infection due to Clostridioides difficile in China. BMC Infect Dis 2021;21:462. [PMID: 34020604 DOI: 10.1186/s12879-021-06171-y] [Reference Citation Analysis]
345 Ereshefsky BJ, Alrahmany D, El Nekidy WS, Pontiggia L, Ghazi IM. Optimal vancomycin dose in the treatment of Clostridium difficile infection, antimicrobial stewardship initiative. J Chemother 2021;33:165-73. [PMID: 32715951 DOI: 10.1080/1120009X.2020.1790166] [Reference Citation Analysis]
346 Kukla M, Adrych K, Dobrowolska A, Mach T, Reguła J, Rydzewska G. Guidelines for Clostridium difficile infection in adults. Prz Gastroenterol 2020;15:1-21. [PMID: 32215122 DOI: 10.5114/pg.2020.93629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
347 Normington C, Moura IB, Bryant JA, Ewin DJ, Clark EV, Kettle MJ, Harris HC, Spittal W, Davis G, Henn MR, Ford CB, Wilcox MH, Buckley AM. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. NPJ Biofilms Microbiomes 2021;7:16. [PMID: 33547298 DOI: 10.1038/s41522-021-00184-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
348 Croke L. Guideline for environmental cleaning. AORN J 2019;110:P8-P10. [PMID: 31774164 DOI: 10.1002/aorn.12903] [Reference Citation Analysis]
349 Kociolek LK, Burnham CD, Nicholson MR, Zackular JP. Clostridioides difficile Infection in Children: Research Progress, Pitfalls, and Priorities. J Pediatric Infect Dis Soc 2021;10:S1-2. [PMID: 34791394 DOI: 10.1093/jpids/piab090] [Reference Citation Analysis]
350 Gonzales-Luna AJ, Olaitan AO, Shen WJ, Deshpande A, Carlson TJ, Dotson KM, Lancaster C, Begum K, Alam MJ, Hurdle JG, Garey KW. Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection. Open Forum Infect Dis 2021;8:ofab365. [PMID: 34381844 DOI: 10.1093/ofid/ofab365] [Reference Citation Analysis]
351 Ship N, Millette M, Carrière S. Rhetoric or Rhetoric: Interpreting Cross-Sectional Data When There Are Disparate Control Groups. Open Forum Infect Dis 2019;6:ofz127. [PMID: 31041342 DOI: 10.1093/ofid/ofz127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
352 Sambri V, Gateau C, Zannoli S, Dirani G, Couturier J, Op den Buijs I, Roymans R, Hallet E, Arnold M, Zumoberhaus A, Steiner S, van de Bovenkamp J, Altwegg M, Berlinger L, Barbut F; revogene C. Difficile study group. Diagnosing Clostridioides difficile infections with molecular diagnostics: multicenter evaluation of revogene C. difficile assay. Eur J Clin Microbiol Infect Dis 2020;39:1169-75. [PMID: 32062723 DOI: 10.1007/s10096-020-03829-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
353 Feeney ME, Thompson M, Gerlach AT, Rushing A, Evans DC, Eiferman DS, Murphy CV. Evaluation of Rectal Vancomycin Irrigation for Treatment of Clostridioides difficile Infection in Patients Post-Colectomy for Toxic Colitis. Surg Infect (Larchmt) 2019;20:411-5. [PMID: 30900947 DOI: 10.1089/sur.2018.265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
354 Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res 2021;19:323-31. [PMID: 32806875 DOI: 10.5217/ir.2020.00039] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
355 Barron J, Lattes A, Marcus EL. Rash induced by enteral vancomycin therapy in an older patient in a long-term care ventilator unit: case report and review of the literature. Allergy Asthma Clin Immunol 2018;14:73. [PMID: 30450116 DOI: 10.1186/s13223-018-0293-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
356 Bozkurt HS, Kara B. Combination of oral vancomycin and intra-colonic vancomycin: Successful treatment of complicated pseudomembranous colitis in a child patient. SAGE Open Med Case Rep 2019;7:2050313X19838442. [PMID: 30911393 DOI: 10.1177/2050313X19838442] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
357 Gurram B, Sue PK. Fecal microbiota transplantation in children: current concepts. Curr Opin Pediatr 2019;31:623-9. [PMID: 31169545 DOI: 10.1097/MOP.0000000000000787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
358 Carter KA, Malani AN. Laxative use and testing for Clostridium difficile in hospitalized adults: An opportunity to improve diagnostic stewardship. Am J Infect Control 2019;47:170-4. [PMID: 30301657 DOI: 10.1016/j.ajic.2018.08.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
359 McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Auninš JG, Trucksis M. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis 2021;72:2132-40. [PMID: 32255488 DOI: 10.1093/cid/ciaa387] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
360 Sheffield ME, Jones BM, Terrell B, Wagner JL, Bland CM. Influence of Probiotics on the Development of Clostridioides difficile Infection in Patients Receiving Fluoroquinolones. Pharmacy (Basel) 2021;9:141. [PMID: 34449745 DOI: 10.3390/pharmacy9030141] [Reference Citation Analysis]
361 Xu X, Godoy-Ruiz R, Adipietro KA, Peralta C, Ben-Hail D, Varney KM, Cook ME, Roth BM, Wilder PT, Cleveland T, Grishaev A, Neu HM, Michel SLJ, Yu W, Beckett D, Rustandi RR, Lancaster C, Loughney JW, Kristopeit A, Christanti S, Olson JW, MacKerell AD, Georges AD, Pozharski E, Weber DJ. Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly. Proc Natl Acad Sci U S A 2020;117:1049-58. [PMID: 31896582 DOI: 10.1073/pnas.1919490117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
362 Non LR, Ince D. Infectious Gastroenteritis in Transplant Patients. Gastroenterol Clin North Am 2021;50:415-30. [PMID: 34024449 DOI: 10.1016/j.gtc.2021.02.013] [Reference Citation Analysis]
363 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
364 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Axenfeld E, Greendyke WG, Li J, Green DA, Whittier S, Freedberg DE. Burden and risk factors for inappropriate Clostridioides Difficile infection testing among hospitalized patients. Diagn Microbiol Infect Dis 2021;99:115283. [PMID: 33360514 DOI: 10.1016/j.diagmicrobio.2020.115283] [Reference Citation Analysis]
366 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
367 Johnson TM, Molina KC, Howard AH, Schwarz K, Allen L, Huang M, Bajrovic V, Miller MA. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin Infect Dis 2021:ciab674. [PMID: 34665248 DOI: 10.1093/cid/ciab674] [Reference Citation Analysis]
368 Ma Y, Yang JY, Peng X, Xiao KY, Xu Q, Wang C. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. J Dig Dis 2020;21:69-80. [PMID: 31875427 DOI: 10.1111/1751-2980.12839] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
369 Solanky D, Pardi DS, Loftus EV, Khanna S. Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis 2019;25:610-9. [PMID: 30260451 DOI: 10.1093/ibd/izy291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
370 Luo Y, Cheong E, Bian Q, Collins DA, Ye J, Shin JH, Yam WC, Takata T, Song X, Wang X, Kamboj M, Gottlieb T, Jiang J, Riley TV, Tang YW, Jin D. Different molecular characteristics and antimicrobial resistance profiles of Clostridium difficile in the Asia-Pacific region. Emerg Microbes Infect 2019;8:1553-62. [PMID: 31662120 DOI: 10.1080/22221751.2019.1682472] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
371 Fawley J, Napolitano LM. Vancomycin Enema in the Treatment of Clostridium difficile Infection. Surg Infect (Larchmt) 2019;20:311-6. [PMID: 30716016 DOI: 10.1089/sur.2018.238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
372 García-Fernández S, Frentrup M, Steglich M, Gonzaga A, Cobo M, López-Fresneña N, Cobo J, Morosini MI, Cantón R, Del Campo R, Nübel U. Whole-genome sequencing reveals nosocomial Clostridioides difficile transmission and a previously unsuspected epidemic scenario. Sci Rep 2019;9:6959. [PMID: 31061423 DOI: 10.1038/s41598-019-43464-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
373 Episcopia B, Gupta A, Fornek M, Kaminski M, Malik S, Sunny S, Landman D, Xavier G, Quale J. Trends in Healthcare Facility-Onset Clostridioides difficile Infection and the Impact of Testing Schemes in an Acute Care Hospital System in New York City, 2016-2019. Am J Infect Control 2021:S0196-6553(21)00118-8. [PMID: 33716096 DOI: 10.1016/j.ajic.2021.03.003] [Reference Citation Analysis]
374 Legenza L, Barnett S, Rose W, Safdar N, Emmerling T, Peh KH, Coetzee R. Clostridium difficile infection perceptions and practices: a multicenter qualitative study in South Africa. Antimicrob Resist Infect Control 2018;7:125. [PMID: 30386594 DOI: 10.1186/s13756-018-0425-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
375 Suda KJ, Clore GS, Evans CT, Reisinger HS, Kale I, Echevarria K, Sherlock SH, Perencevich EN, Goetz MB; VA-CDC Practice-Based Research Network. Acceptability and effectiveness of antimicrobial stewardship implementation strategies on fluoroquinolone prescribing. Infect Control Hosp Epidemiol 2021;:1-8. [PMID: 33843527 DOI: 10.1017/ice.2021.10] [Reference Citation Analysis]
376 Khanna S, Pardi D. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era. Am J Gastroenterol 2020;115:971-4. [PMID: 32618640 DOI: 10.14309/ajg.0000000000000689] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
377 Sandlund J, Estis J, Katzenbach P, Nolan N, Hinson K, Herres J, Pero T, Peterson G, Schumaker JM, Stevig C, Warren R, West T, Chow SK. Increased Clinical Specificity with Ultrasensitive Detection of Clostridioides difficile Toxins: Reduction of Overdiagnosis Compared to Nucleic Acid Amplification Tests. J Clin Microbiol 2019;57:e00945-19. [PMID: 31434726 DOI: 10.1128/JCM.00945-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
378 Shin JH, Chaplin AS, Hays RA, Kolling GL, Vance S, Guerrant RL, Archbald-Pannone L, Warren CA. Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent Clostridioides difficile Infection Patients for Fecal Microbiota Transplant: A Retrospective Cohort Analysis. J Clin Med 2019;8:E1036. [PMID: 31315214 DOI: 10.3390/jcm8071036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
379 Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol 2021;14:17562848211018654. [PMID: 34104214 DOI: 10.1177/17562848211018654] [Reference Citation Analysis]
380 Huttner BD, de Lastours V, Wassenberg M, Maharshak N, Mauris A, Galperine T, Zanichelli V, Kapel N, Bellanger A, Olearo F, Duval X, Armand-Lefevre L, Carmeli Y, Bonten M, Fantin B, Harbarth S; R-Gnosis WP3 study group. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect 2019;25:830-8. [PMID: 30616014 DOI: 10.1016/j.cmi.2018.12.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 18.7] [Reference Citation Analysis]
381 Brandburg GL. Antimicrobial prescribing in older adults. Nurse Pract 2019;44:42-8. [PMID: 30672866 DOI: 10.1097/01.NPR.0000524666.24469.d1] [Reference Citation Analysis]
382 Surana NK. Moving Microbiome Science from the Bench to the Bedside: a Physician-Scientist Perspective. mSystems 2019;4:e00160-19. [PMID: 31138724 DOI: 10.1128/mSystems.00160-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
383 Schramm VL. Enzymatic Transition States and Drug Design. Chem Rev 2018;118:11194-258. [PMID: 30335982 DOI: 10.1021/acs.chemrev.8b00369] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
384 Johnson SW, Brown SV, Priest DH. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure. Clin Infect Dis 2020;71:1133-9. [PMID: 31560051 DOI: 10.1093/cid/ciz966] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
385 Shrestha MP, Taleban S. Colectomy Rates Are Increasing Among Inpatients With Concomitant Ulcerative Colitis and Clostridioides difficile. Journal of Clinical Gastroenterology 2021;55:709-15. [DOI: 10.1097/mcg.0000000000001412] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
386 Sperling K, Priddy A, Suntharam N, Feuerhake T. Optimizing testing for Clostridium difficile infection: A quality improvement project. Am J Infect Control 2019;47:340-2. [PMID: 30420098 DOI: 10.1016/j.ajic.2018.08.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
387 Pahud BA, Hassan F, Harrison CJ, Halasa NB, Chappell JD, Englund JA, Klein EJ, Szilagyi PG, Weinberg GA, Sherman AK, Polage C, Wikswo ME, McDonald LC, Payne DC, Selvarangan R. Detection of Clostridioides difficile by Real-time PCR in Young Children Does Not Predict Disease. Hosp Pediatr 2020;10:555-62. [PMID: 32482733 DOI: 10.1542/hpeds.2020-0012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
388 Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021;73:755-7. [PMID: 34492699 DOI: 10.1093/cid/ciab718] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
389 Kraft CS, Parrott JS, Cornish NE, Rubinstein ML, Weissfeld AS, McNult P, Nachamkin I, Humphries RM, Kirn TJ, Dien Bard J, Lutgring JD, Gullett JC, Bittencourt CE, Benson S, Bobenchik AM, Sautter RL, Baselski V, Atlas MC, Marlowe EM, Miller NS, Fischer M, Richter SS, Gilligan P, Snyder JW. A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults. Clin Microbiol Rev 2019;32:e00032-18. [PMID: 31142497 DOI: 10.1128/CMR.00032-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
390 Dieterle MG, Rao K, Young VB. Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Ann N Y Acad Sci 2019;1435:110-38. [PMID: 30238983 DOI: 10.1111/nyas.13958] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
391 Papić N, Jelovčić F, Karlović M, Marić LS, Vince A. Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection. Eur J Clin Microbiol Infect Dis 2020;39:569-74. [DOI: 10.1007/s10096-019-03759-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
392 Ahmad O, Crawford TN, Arora V, Maskey MK. Laboratory markers predictive of fulminant Clostridioides difficile infection refractory to fluid resuscitation. Infect Prev Pract 2021;3:100127. [PMID: 34368744 DOI: 10.1016/j.infpip.2021.100127] [Reference Citation Analysis]
393 Lala VG, Bobat B, Haagensen M, Kathan P, Mahomed A. Metronidazole-induced encephalopathy. SA J Radiol 2021;25:2016. [PMID: 33824746 DOI: 10.4102/sajr.v25i1.2016] [Reference Citation Analysis]
394 Maser B, Pelland-Marcotte MC, Alexander S, Sung L, Gupta S. Levofloxacin prophylaxis in hospitalized children with leukemia: A cost-utility analysis. Pediatr Blood Cancer 2020;67:e28643. [PMID: 32785971 DOI: 10.1002/pbc.28643] [Reference Citation Analysis]
395 Aujla AK, Averbukh LD, Potashinsky A, Rossi L. A Rare Case of Clostridium difficile Enteritis: A Common Bug in an Uncommon Place. Cureus 2019;11:e4519. [PMID: 31259128 DOI: 10.7759/cureus.4519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
396 Kutty PK, Beekmann SE, Sinkowitz-cochran RL, Dubberke ER, Kuhar DT, Mcdonald LC, Polgreen PM. A national survey of testing and management of asymptomatic carriage of C. difficile. Infect Control Hosp Epidemiol 2019;40:801-3. [DOI: 10.1017/ice.2019.109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
397 Novakova E, Stofkova Z, Sadlonova V, Hleba L. Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample. Antibiotics (Basel) 2021;10:1035. [PMID: 34572617 DOI: 10.3390/antibiotics10091035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Ochoa-Hein E, Sifuentes-Osornio J, Ponce de León-Garduño A, Torres-González P, Granados-García V, Galindo-Fraga A. Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study. PLoS One 2018;13:e0198212. [PMID: 29813115 DOI: 10.1371/journal.pone.0198212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
399 Matchett WE, Anguiano-Zarate S, Malewana GBR, Mudrick H, Weldy M, Evert C, Khoruts A, Sadowsky M, Barry MA. A Replicating Single-Cycle Adenovirus Vaccine Effective against Clostridium difficile. Vaccines (Basel) 2020;8:E470. [PMID: 32842679 DOI: 10.3390/vaccines8030470] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Shuai H, Bian Q, Luo Y, Zhou X, Song X, Ye J, Huang Q, Peng Z, Wu J, Jiang J, Jin D. Molecular characteristics of Clostridium difficile in children with acute gastroenteritis from Zhejiang. BMC Infect Dis 2020;20:343. [PMID: 32404060 DOI: 10.1186/s12879-020-05030-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
401 Cheng Y, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clinical Gastroenterology and Hepatology 2021;19:1627-34. [DOI: 10.1016/j.cgh.2020.06.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
402 Mullane KM, Dubberke ER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant 2019;33:e13564. [PMID: 31002420 DOI: 10.1111/ctr.13564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
403 Miller WD, Keskey R, Alverdy JC. Sepsis and the Microbiome: A Vicious Cycle. J Infect Dis 2021;223:S264-9. [PMID: 33330900 DOI: 10.1093/infdis/jiaa682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
404 Hirano R, Sakanaka M, Yoshimi K, Sugimoto N, Eguchi S, Yamauchi Y, Nara M, Maeda S, Ami Y, Gotoh A, Katayama T, Iida N, Kato T, Ohno H, Fukiya S, Yokota A, Nishimoto M, Kitaoka M, Nakai H, Kurihara S. Next-generation prebiotic promotes selective growth of bifidobacteria, suppressing Clostridioides difficile. Gut Microbes 2021;13:1973835. [PMID: 34553672 DOI: 10.1080/19490976.2021.1973835] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis 2019;19:265-74. [PMID: 30709665 DOI: 10.1016/S1473-3099(18)30614-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
406 Parmar D, Dang R, Miranda-Katz M, Alabaster A, Greenhow TL. Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children. Pediatr Infect Dis J 2019;38:1073-8. [PMID: 31626042 DOI: 10.1097/INF.0000000000002439] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
407 Hoffmann DE. Introduction: The Promise and Challenges of Microbiome-Based Therapies. J Law Med Ethics 2019;47:476-81. [PMID: 31957585 DOI: 10.1177/1073110519897725] [Reference Citation Analysis]
408 Elangovan A, Fischer M. When to use probiotics in luminal gastrointestinal disorders? Curr Opin Clin Nutr Metab Care 2020;23:336-43. [PMID: 32657791 DOI: 10.1097/MCO.0000000000000674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Lenggenhager L, Zanella MC, Poncet A, Kaiser L, Schrenzel J. Discordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland. BMJ Open 2020;10:e036342. [PMID: 32928850 DOI: 10.1136/bmjopen-2019-036342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
410 Guh AY, Kutty PK. Clostridioides difficile Infection. Ann Intern Med 2018;169:ITC49-64. [PMID: 30285209 DOI: 10.7326/AITC201810020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
411 Scaria E, Barker AK, Alagoz O, Safdar N. Association of Visitor Contact Precautions With Estimated Hospital-Onset Clostridioides difficile Infection Rates in Acute Care Hospitals. JAMA Netw Open 2021;4:e210361. [PMID: 33635330 DOI: 10.1001/jamanetworkopen.2021.0361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Xiao Y, Liu Y, Qin X. Comparative Study of Clostridium difficile Clinical Detection Methods in Patients with Diarrhoea. Can J Infect Dis Med Microbiol 2020;2020:8753284. [PMID: 32064010 DOI: 10.1155/2020/8753284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
413 Chaar A, Feuerstadt P. Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211011953. [PMID: 33995583 DOI: 10.1177/17562848211011953] [Reference Citation Analysis]
414 . Hygienemaßnahmen bei Clostridioides difficile-Infektion (CDI): Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsbl 2019;62:906-23. [DOI: 10.1007/s00103-019-02959-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
415 Moura IB, Normington C, Ewin D, Clark E, Wilcox MH, Buckley AM, Chilton CH. Method comparison for the direct enumeration of bacterial species using a chemostat model of the human colon. BMC Microbiol 2020;20:2. [PMID: 31898476 DOI: 10.1186/s12866-019-1669-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
416 Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L, Maleki A, Kouhsari E. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2020;9:158. [PMID: 32977835 DOI: 10.1186/s13756-020-00815-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
417 Howard A, Rychalsky MR, Murray TS. Persistent Leg Drainage in a Pediatric Trauma Patient. Pediatr Infect Dis J 2021;40:597-9. [PMID: 33956759 DOI: 10.1097/INF.0000000000003004] [Reference Citation Analysis]
418 Kelly CP, Poxton IR, Shen J, Wilcox MH, Gerding DN, Zhao X, Laterza OF, Railkar R, Guris D, Dorr MB. Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection. Clin Infect Dis 2020;71:81-6. [PMID: 31628838 DOI: 10.1093/cid/ciz809] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
419 Rhea S, Hilscher R, Rineer JI, Munoz B, Jones K, Endres-Dighe SM, DiBiase LM, Sickbert-Bennett EE, Weber DJ, MacFarquhar JK, Dubendris H, Bobashev G. Creation of a Geospatially Explicit, Agent-based Model of a Regional Healthcare Network with Application to Clostridioides difficile Infection. Health Secur 2019;17:276-90. [PMID: 31433281 DOI: 10.1089/hs.2019.0021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
420 Cornely OA, Mullane KM, Birch T, Hazan-Steinberg S, Nathan R, Bouza E, Calfee DP, Ellison MC, Wong MT, Dorr MB. Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer. Open Forum Infect Dis 2020;7:ofaa038. [PMID: 32099847 DOI: 10.1093/ofid/ofaa038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
421 McQuade JL, Ologun GO, Arora R, Wargo JA. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep 2020;22:74. [PMID: 32577835 DOI: 10.1007/s11912-020-00913-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
422 Revolinski SL, Munoz-Price LS. Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention. Clin Infect Dis 2019;68:2144-53. [PMID: 30281082 DOI: 10.1093/cid/ciy845] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
423 Deshpande A, Wu X, Huo W, Palmer KL, Hurdle JG. Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases. Antimicrob Agents Chemother 2020;64:e00415-20. [PMID: 32457109 DOI: 10.1128/AAC.00415-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
424 Sullivan KV. Diagnostic Stewardship in Clinical Microbiology, Essential Partner to Antimicrobial Stewardship. Clinical Chemistry 2022;68:75-82. [DOI: 10.1093/clinchem/hvab206] [Reference Citation Analysis]
425 Qutub M, Govindan P, Vattappillil A. Effectiveness of a Two-Step Testing Algorithm for Reliable and Cost-Effective Detection of Clostridium difficile Infection in a Tertiary Care Hospital in Saudi Arabia. Med Sci (Basel) 2019;7:E6. [PMID: 30626129 DOI: 10.3390/medsci7010006] [Reference Citation Analysis]
426 Demir KK, Cheng MP, Lee TC. Predictive factors of Clostridioides difficile infection in hospitalized patients with new diarrhea: A retrospective cohort study. PLoS One 2018;13:e0207128. [PMID: 30517148 DOI: 10.1371/journal.pone.0207128] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 Shin JH, Warren CA. Prevention and treatment of recurrent Clostridioides difficile infection. Curr Opin Infect Dis 2019;32:482-9. [PMID: 31369420 DOI: 10.1097/QCO.0000000000000587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
428 Stelck B. [86/m-Watery diarrhea : Preparation for the medical specialist examination: part 61]. Internist (Berl) 2021;62:412-7. [PMID: 33860808 DOI: 10.1007/s00108-021-01020-1] [Reference Citation Analysis]
429 Meza-Torres J, Auria E, Dupuy B, Tremblay YDN. Wolf in Sheep's Clothing: Clostridioides difficile Biofilm as a Reservoir for Recurrent Infections. Microorganisms 2021;9:1922. [PMID: 34576818 DOI: 10.3390/microorganisms9091922] [Reference Citation Analysis]
430 Stavropoulou E, Bezirtzoglou E. Probiotics in Medicine: A Long Debate. Front Immunol 2020;11:2192. [PMID: 33072084 DOI: 10.3389/fimmu.2020.02192] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
431 Tariq R, Hayat M, Pardi D, Khanna S. Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2021;40:1383-92. [PMID: 33496893 DOI: 10.1007/s10096-021-04163-z] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
432 Chiu CY, Sarwal A, Feinstein A, Hennessey K. Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Antibiotics (Basel) 2019;8:E173. [PMID: 31581576 DOI: 10.3390/antibiotics8040173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
433 Borsky AE, Flores EJ, Berliner E, Chang C, Umscheid CA, Chang SM. Next Steps in Improving Healthcare Value: AHRQ Evidence-based Practice Center Program-Applying the Knowledge to Practice to Data Cycle to Strengthen the Value of Patient Care. J Hosp Med 2019;14:311-4. [PMID: 30794140 DOI: 10.12788/jhm.3157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
434 Lee HS, Plechot K, Gohil S, Le J. Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis. Infect Dis Ther 2021;10:687-97. [PMID: 33770398 DOI: 10.1007/s40121-021-00417-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
435 Trinh TD, Strnad L, Damon L, Dzundza JH, Graff LR, Griffith LM, Hilts-Horeczko A, Olin R, Shenoy S, DeVoe C, Wang L, Rodriguez-Monguio R, Gu TM, Hampton SR, Macapinlac BAC, Yang K, Doernberg SB. Reductions in vancomycin and meropenem following the implementation of a febrile neutropenia management algorithm in hospitalized adults: An interrupted time series analysis. Infect Control Hosp Epidemiol 2021;:1-8. [PMID: 33487182 DOI: 10.1017/ice.2020.1368] [Reference Citation Analysis]
436 Mehta SR, Yen EF. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Transl Res 2021;230:197-207. [PMID: 33278650 DOI: 10.1016/j.trsl.2020.11.013] [Reference Citation Analysis]
437 Alukal J, Dutta SK, Surapaneni BK, Le M, Tabbaa O, Phillips L, Mattar MC. Safety and efficacy of fecal microbiota transplant in 9 critically ill patients with severe and complicated Clostridium difficile infection with impending colectomy. J Dig Dis 2019;20:301-7. [DOI: 10.1111/1751-2980.12750] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
438 Elangovan A, Allegretti JR, Fischer M. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. Expert Opin Biol Ther 2019;19:1343-55. [PMID: 31570017 DOI: 10.1080/14712598.2019.1673725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
439 Greene MT, Krein SL, Huis A, Hulscher M, Sax H, Sakamoto F, Sakihama T, Tokuda Y, Fowler KE, Saint S. Infection prevention practices in the United States, the Netherlands, Switzerland, and Japan: Results from national surveys. Infect Control Hosp Epidemiol 2021;:1-9. [PMID: 33536105 DOI: 10.1017/ice.2020.1395] [Reference Citation Analysis]
440 Al Momani LA, Abughanimeh O, Boonpheng B, Gabriel JG, Young M. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review. Cureus 2018;10:e2778. [PMID: 30112254 DOI: 10.7759/cureus.2778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
441 Leung J, Pham S. A Systematic Review of Fecal Microbiota Transplantation Versus Vancomycin for Treatment of Recurrent Clostridioides difficile Infection. Gastroenterol Nurs 2021;44:106-15. [PMID: 33795620 DOI: 10.1097/SGA.0000000000000529] [Reference Citation Analysis]
442 Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: Past, present and future. World J Gastroenterol 2020; 26(8): 777-788 [PMID: 32148376 DOI: 10.3748/wjg.v26.i8.777] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
443 Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2019;17:2722-2730.e4. [PMID: 30448597 DOI: 10.1016/j.cgh.2018.11.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
444 Khanna S, Gerding DN. Current and future trends in clostridioides (clostridium) difficile infection management. Anaerobe 2019;58:95-102. [PMID: 31054313 DOI: 10.1016/j.anaerobe.2019.04.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
445 Granata G, Donno DR. Introduction to the Special Issue on Clostridioides difficile. Antibiotics (Basel) 2021;10:1233. [PMID: 34680813 DOI: 10.3390/antibiotics10101233] [Reference Citation Analysis]
446 Kechagias KS, Chorepsima S, Triarides NA, Falagas ME. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis 2020;39:1053-8. [DOI: 10.1007/s10096-019-03756-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
447 Baus CJ, Schulz LT, Lepak AJ, Safdar N. Letter to the Editor: Response to Maziade et al; Enhanced Clostridioides difficile infection prevention with a pharmacy-controlled policy that adds a three-strain Lactobacillus probiotic concomitantly to antibiotic therapy. Clin Infect Dis 2021:ciab661. [PMID: 34320158 DOI: 10.1093/cid/ciab661] [Reference Citation Analysis]
448 Collins DA, Riley TV. Clostridium difficile in Asia: Opportunities for One Health Management. Trop Med Infect Dis 2018;4:E7. [PMID: 30597880 DOI: 10.3390/tropicalmed4010007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
449 Asano S, Katsura M. Determining the optimal surgical timing of fulminant Clostridium difficile colitis by using four objective factors and computed tomography findings: A case report. Int J Surg Case Rep 2021;80:105633. [PMID: 33609944 DOI: 10.1016/j.ijscr.2021.02.019] [Reference Citation Analysis]
450 Han SH, Yi J, Kim JH, Moon AH. Investigation of Intestinal Microbiota and Fecal Calprotectin in Non-Toxigenic and Toxigenic Clostridioides difficile Colonization and Infection. Microorganisms 2020;8:E882. [PMID: 32545219 DOI: 10.3390/microorganisms8060882] [Reference Citation Analysis]
451 Alvarez AM, Rathore MH. Clostridium difficile Infection in Children. Adv Pediatr 2019;66:263-80. [PMID: 31230698 DOI: 10.1016/j.yapd.2019.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
452 Liu Y, Alnababtah K, Cook S, Yu Y. Healthcare providers' perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review. Therap Adv Gastroenterol 2021;14:17562848211042679. [PMID: 34567271 DOI: 10.1177/17562848211042679] [Reference Citation Analysis]
453 Hengel RL, Ritter TE, Nathan RV, Van Anglen LJ, Schroeder CP, Dillon RJ, Marcella SW, Garey KW. Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study. Open Forum Infect Dis 2020;7:ofaa097. [PMID: 32363211 DOI: 10.1093/ofid/ofaa097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
454 Abreu Y Abreu AT, Velarde-Ruiz Velasco JA, Zavala-Solares MR, Remes-Troche JM, Carmona-Sánchez RI, Aldana-Ledesma JM, Camacho-Ortiz A, Contreras-Omaña R, Díaz-Seoane R, Elizondo-Vázquez CT, Garza-González E, Grajales-Figueroa G, Gómez-Escudero O, Jacobo-Karam JS, Morales-Arámbula M, Olivares-Guzmán LO, Sifuentes-Osornio J, Siu-Moguel AG, Soto-Solís R, Valdovinos-García LR, Valdovinos-Díaz MA, Vázquez-Elizondo G, Lazo-de la Vega Jasso SA. Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed) 2019;84:204-19. [PMID: 30987771 DOI: 10.1016/j.rgmx.2018.12.001] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
455 Jakobs F, Wingen-Heimann SM, Jeck J, Kron A, Cornely OA, Kron F. A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany. BMC Health Serv Res 2021;21:939. [PMID: 34496836 DOI: 10.1186/s12913-021-06970-8] [Reference Citation Analysis]
456 Ho M, Moon D, Pires-Alves M, Thornton PD, McFarlin BL, Wilson BA. Recovery of microbial community profile information hidden in chimeric sequence reads. Comput Struct Biotechnol J 2021;19:5126-39. [PMID: 34589188 DOI: 10.1016/j.csbj.2021.08.050] [Reference Citation Analysis]
457 Rzucidło-Hymczak A, Hymczak H, Olechowska-Jarząb A, Gorczyca A, Kapelak B, Drwiła R, Plicner D. Clostridioides difficile infection after cardiac surgery: Assessment of prevalence, risk factors and clinical outcomes-retrospective study. PeerJ 2020;8:e9972. [PMID: 33062429 DOI: 10.7717/peerj.9972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Meier JL. Viral Acute Gastroenteritis in Special Populations. Gastroenterol Clin North Am 2021;50:305-22. [PMID: 34024443 DOI: 10.1016/j.gtc.2021.02.003] [Reference Citation Analysis]
459 Sullivan KV, Gallagher JC, Leekha S, Morgan DJ, Morita K, Rock C, Claeys KC. Use of diagnostic and antimicrobial stewardship practices to improve Clostridioides difficile testing among SHEA Research Network hospitals. Infect Control Hosp Epidemiol 2021;:1-5. [PMID: 34376271 DOI: 10.1017/ice.2021.133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
460 Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, Nistor-Cseppento DC, Rus M, Pavel FM, Tit DM. Risk Factors Associated with Recurrent Clostridioides difficile Infection. Healthcare (Basel) 2020;8:E352. [PMID: 32967323 DOI: 10.3390/healthcare8030352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
461 Majeed A, Larriva MM, Iftikhar A, Mushtaq A, Campbell P, Nadeem Malik M, Rafae A, Zar MA, Kamal A, Lakhani M, Khalid NR, Zangeneh TT, Anwer F. A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients. Infect Dis Clin Pract (Baltim Md) 2020;28:10-5. [PMID: 33424210 DOI: 10.1097/ipc.0000000000000798] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
462 Gonzales-Luna AJ, Spinler JK, Oezguen N, Khan MAW, Danhof HA, Endres BT, Alam MJ, Begum K, Lancaster C, Costa GP, Savidge TC, Hurdle JG, Britton R, Garey KW. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe 2021;70:102387. [PMID: 34044101 DOI: 10.1016/j.anaerobe.2021.102387] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 Bolukcu S, Hakyemez IN, Gultepe BS, Okay G, Durdu B, Koc MM, Aslan T. Clostridium difficile infection: Is there a change in the underlying factors? Inflammatory bowel disease and Clostridium difficile. Saudi J Gastroenterol 2019;25:384-9. [PMID: 31793457 DOI: 10.4103/sjg.SJG_44_19] [Reference Citation Analysis]
464 Girão ES, de Melo Tavares B, Alves dos Santos S, Gamarra GL, Rizek C, Martins RC, Perdigão Neto LV, Diogo C, Annibale Orsi TD, Sanchez Espinoza EP, Paz Morales HM, da Silva Nogueira K, Maestri AC, Boszczowski I, Piastrelli F, Costa CL, Costa DV, Maciel G, Romão J, Guimarães T, Anne de Castro Brito G, Costa SF. Prevalence of Clostridioides difficile associated diarrhea in hospitalized patients in five Brazilian centers: A multicenter, prospective study. Anaerobe 2020;66:102267. [DOI: 10.1016/j.anaerobe.2020.102267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
465 Novosad SA, Mu Y, Winston LG, Johnston H, Basiliere E, Olson DM, Farley MM, Revis A, Wilson L, Perlmutter R, Holzbauer SM, Whitten T, Phipps EC, Dumyati GK, Beldavs ZG, Ocampo VLS, Davis CM, Kainer M, Gerding DN, Guh AY. Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015. J Gen Intern Med 2020;35:412-9. [PMID: 31768906 DOI: 10.1007/s11606-019-05386-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
466 Kao D, Wong K, Franz R, Cochrane K, Sherriff K, Chui L, Lloyd C, Roach B, Bai AD, Petrof EO, Allen-Vercoe E. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol 2021;6:282-91. [PMID: 33631102 DOI: 10.1016/S2468-1253(21)00007-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
467 Mondal SI, Akter A, Draper LA, Ross RP, Hill C. Characterization of an Endolysin Targeting Clostridioides difficile That Affects Spore Outgrowth. Int J Mol Sci 2021;22:5690. [PMID: 34073633 DOI: 10.3390/ijms22115690] [Reference Citation Analysis]
468 Ramos CP, Diniz AN, Leite SM, Lobato FCF, Pereira ST, Rennó MC, de Oliveira Ferreira E, Silva ROS. Evaluation of an immunochromatographic test for the detection of glutamate dehydrogenase for the diagnosis of Clostridioides (Clostridium) difficile infection in dogs. Braz J Microbiol 2021;52:2555-8. [PMID: 34562233 DOI: 10.1007/s42770-021-00615-y] [Reference Citation Analysis]
469 Phatharacharukul P, Purpura RD, Gandhi D, Xu H, Bickett-Burkhart K, Chalasani N, Fischer M, Orman ES. Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis. Clin Transl Gastroenterol 2020;11:e00189. [PMID: 32675703 DOI: 10.14309/ctg.0000000000000189] [Reference Citation Analysis]
470 Catho G, Huttner BD. Strategies for the eradication of extended-spectrum beta-lactamase or carbapenemase-producing Enterobacteriaceae intestinal carriage. Expert Rev Anti Infect Ther 2019;17:557-69. [PMID: 31313610 DOI: 10.1080/14787210.2019.1645007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
471 Hamada M, Yamaguchi T, Ishii Y, Chono K, Tateda K. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile. J Infect Chemother 2020;26:685-92. [PMID: 32224190 DOI: 10.1016/j.jiac.2020.02.014] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
472 Ganley JG, Derbyshire ER. Linking Genes to Molecules in Eukaryotic Sources: An Endeavor to Expand Our Biosynthetic Repertoire. Molecules 2020;25:E625. [PMID: 32023950 DOI: 10.3390/molecules25030625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Saha S, Mara K, Pardi DS, Khanna S. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology 2021;160:1961-1969.e3. [PMID: 33444573 DOI: 10.1053/j.gastro.2021.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
474 Dennis EK, Chaturvedi S, Chaturvedi V. So Many Diagnostic Tests, So Little Time: Review and Preview of Candida auris Testing in Clinical and Public Health Laboratories. Front Microbiol 2021;12:757835. [PMID: 34691009 DOI: 10.3389/fmicb.2021.757835] [Reference Citation Analysis]
475 Theiss AM, Balla A, Ross A, Francis D, Wojewoda C. Searching for a Potential Algorithm for Clostridium difficile Testing at a Tertiary Care Hospital: Does Toxin Enzyme Immunoassay Testing Help? J Clin Microbiol 2018;56:e00415-18. [PMID: 29743303 DOI: 10.1128/JCM.00415-18] [Reference Citation Analysis]
476 Naclerio GA, Abutaleb NS, Li D, Seleem MN, Sintim HO. Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo. J Med Chem 2020;63:11934-44. [PMID: 32960605 DOI: 10.1021/acs.jmedchem.0c01198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
477 Kim B, Kim J, Pai H. Association between Antibiotic Consumption and Incidence of Clostridioides difficile Infection in a Hospital. J Korean Med Sci 2020;35:e407. [PMID: 33289370 DOI: 10.3346/jkms.2020.35.e407] [Reference Citation Analysis]
478 Adelman MW, Goodenough D, Sefton S, Mackey C, Thomas S, Fridkin SK, Woodworth MH. Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018. Anaerobe 2021;70:102364. [PMID: 33862203 DOI: 10.1016/j.anaerobe.2021.102364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
479 Morgan JR, Carey KM, Barlam TF, Christiansen CL, Drainoni ML. Inappropriate Antibiotic Prescribing for Acute Bronchitis in Children and Impact on Subsequent Episodes of Care and Treatment. Pediatr Infect Dis J 2019;38:271-4. [PMID: 29794648 DOI: 10.1097/INF.0000000000002117] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
480 McCauley BP, Evans ME, Simbartl LA, Gamage SD, Kralovic SM, Roselle GA. Effect of testing methods on incidence of Clostridioides difficile infection rates in Veterans' Affairs medical centers. Infect Control Hosp Epidemiol 2021;42:461-3. [PMID: 33185177 DOI: 10.1017/ice.2020.452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
481 Origüen J, Orellana MÁ, Fernández-Ruiz M, Corbella L, San Juan R, Ruiz-Ruigómez M, López-Medrano F, Lizasoain M, Ruiz-Merlo T, Maestro-de la Calle G, Parra P, Villa J, Delgado R, Aguado JM. Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in Clostridium difficile Infection: a Retrospective Cohort Study. J Clin Microbiol 2019;57:e01125-18. [PMID: 30463889 DOI: 10.1128/JCM.01125-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
482 Song Y, Himmel B, Öhrmalm L, Gyarmati P. The Microbiota in Hematologic Malignancies. Curr Treat Options Oncol 2020;21:2. [PMID: 31927673 DOI: 10.1007/s11864-019-0693-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
483 Nicholson MR, Hourigan SK, Conrad M, Goyal A, Jensen K, Kelsen J, Kennedy M, Weatherly M, Kahn SA. Current Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. Am J Gastroenterol 2021;116:1954-6. [PMID: 34140459 DOI: 10.14309/ajg.0000000000001350] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
484 Florez ID, Niño-Serna LF, Beltrán-Arroyave CP. Acute Infectious Diarrhea and Gastroenteritis in Children. Curr Infect Dis Rep 2020;22:4. [PMID: 31993758 DOI: 10.1007/s11908-020-0713-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
485 Tamilarasan AG, Krishnananthan T. Faecal microbiota transplantation: what's beyond Clostridium difficile infection? Eur J Gastroenterol Hepatol 2021;33:487-94. [PMID: 33177380 DOI: 10.1097/MEG.0000000000001938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
486 Sandlund J, Davies K, Wilcox MH. Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic Accuracy. J Clin Microbiol 2020;58:e01913-19. [PMID: 32269098 DOI: 10.1128/JCM.01913-19] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
487 Balram B, Battat R, Al-Khoury A, D'Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T. Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Crohns Colitis 2019;13:27-38. [PMID: 30247650 DOI: 10.1093/ecco-jcc/jjy143] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
488 Bernard R, Hourigan SK, Nicholson MR. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients. J Pediatric Infect Dis Soc 2021;10:S58-63. [PMID: 34791396 DOI: 10.1093/jpids/piab056] [Reference Citation Analysis]
489 Suarez-Carantoña C, Rodriguez-Torres A, Viteri-Noel A, Pintado V, Garcia-Fernandez S, Mora-Pimentel D, Escudero-Sanchez R, Martin-Jusdado F, Moreno S, Cobo J. Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile. J Clin Med 2021;10:1627. [PMID: 33921309 DOI: 10.3390/jcm10081627] [Reference Citation Analysis]
490 Mendelsohn RB, Kaltsas A, King S, Hwang C, Kassam Z, Abend AM, Kramer E, Kamboj M. Fecal Microbiota Transplantation Is Safe for Clostridiodies difficile Infection in Patients with Solid Tumors Undergoing Chemotherapy. Dig Dis Sci 2021. [PMID: 34089134 DOI: 10.1007/s10620-021-07024-z] [Reference Citation Analysis]
491 Tan X, Johnson S. Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'. Anaerobe 2019;60:102092. [PMID: 31472233 DOI: 10.1016/j.anaerobe.2019.102092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
492 Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection. J Formos Med Assoc 2021:S0929-6646(21)00498-8. [PMID: 34836663 DOI: 10.1016/j.jfma.2021.11.001] [Reference Citation Analysis]
493 Solanky D, Juang DK, Johns ST, Drobish IC, Mehta SR, Kumaraswamy M. Using diagnostic stewardship to reduce rates, healthcare expenditures and accurately identify cases of hospital-onset Clostridioides difficile infection. Infect Control Hosp Epidemiol 2021;42:51-6. [PMID: 32943129 DOI: 10.1017/ice.2020.375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
494 Klezovich-Bénard M, Bouchand F, Rouveix E, Goossens PL, Davido B. Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care. Eur J Gen Pract 2021;27:320-5. [PMID: 34755587 DOI: 10.1080/13814788.2021.1998447] [Reference Citation Analysis]
495 Fatemi Y, Bergl PA. Diagnostic Stewardship: Appropriate Testing and Judicious Treatments. Crit Care Clin 2022;38:69-87. [PMID: 34794632 DOI: 10.1016/j.ccc.2021.09.002] [Reference Citation Analysis]
496 Saldanha GZ, Pires RN, Rauber AP, de Lima-morales D, Falci DR, Caierão J, Pasqualotto AC, Martins AF. Genetic relatedness, Virulence factors and Antimicrobial Resistance of C. difficile strains from hospitalized patients in a multicentric study in Brazil. Journal of Global Antimicrobial Resistance 2020;22:117-21. [DOI: 10.1016/j.jgar.2020.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
497 Matson V, Chervin CS, Gajewski TF. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology 2021;160:600-13. [PMID: 33253684 DOI: 10.1053/j.gastro.2020.11.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
498 Leedahl DD, Personett HA, Nagpal A, Barreto EF. Prevention of Clostridium difficile Infection in Critically Ill Adults. Pharmacotherapy 2019;39:399-407. [PMID: 30506900 DOI: 10.1002/phar.2200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
499 Girão ES, Vásconez Noguera SL, Sanchez Espinoza EP, Pereira Alves Madeira Bezerra CL, Lino FM, Côrtes MF, Alves Dos Santos S, Paranhos-Baccala G, Perdigão Neto LV, Costa SF. Evaluation of loop-mediated isothermal amplification assay for detection of Clostridioides difficile infection: A prospective diagnostic performance study. Anaerobe 2021;71:102410. [PMID: 34174401 DOI: 10.1016/j.anaerobe.2021.102410] [Reference Citation Analysis]
500 Miller R, Morillas JA, Brizendine KD, Fraser TG. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients. J Clin Microbiol 2020;58:e01764-19. [PMID: 31896665 DOI: 10.1128/JCM.01764-19] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
501 Harbrecht BG. Limitations of the Infectious Disease Society of America/Society for Hospital Epidemiologists of America 2017 Update of Guidelines for the Treatment of Clostridium Difficile Colitis. Dis Colon Rectum 2019;62:1147-9. [PMID: 31490821 DOI: 10.1097/DCR.0000000000001469] [Reference Citation Analysis]
502 Ng KK, Reinert ZE, Corver J, Resurreccion D, Hensbergen PJ, Prescher JA. A Bioluminescent Sensor for Rapid Detection of PPEP-1, a Clostridioides difficile Biomarker. Sensors (Basel) 2021;21:7485. [PMID: 34833562 DOI: 10.3390/s21227485] [Reference Citation Analysis]
503 Brown KA, McGeer A, Schwartz KL, Diong C, Etches J, Garber G, Johnstone J, Langford B, Daneman N. Interfacility patient sharing and Clostridioides difficile infection incidence in the Ontario hospital system: A 13-year cohort study. Infect Control Hosp Epidemiol 2020;41:154-60. [PMID: 31762432 DOI: 10.1017/ice.2019.283] [Reference Citation Analysis]
504 Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Reference Citation Analysis]
505 Dionne JC, Sullivan K, Mbuagbaw L, Takaoka A, Duan EH, Alhazzani W, Devlin JW, Duprey M, Moayyedi P, Armstrong D, Thabane L, Tsang JLY, Jaeschke R, Hamielec C, Karachi T, Cartin-Ceba R, Muscedere J, Alshahrani MSS, Cook DJ. Diarrhoea: interventions, consequences and epidemiology in the intensive care unit (DICE-ICU): a protocol for a prospective multicentre cohort study. BMJ Open 2019;9:e028237. [PMID: 31248929 DOI: 10.1136/bmjopen-2018-028237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
506 van Eijk E, Boekhoud IM, Kuijper EJ, Bos-Sanders IMJG, Wright G, Smits WK. Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile. Antimicrob Agents Chemother 2019;63:e01363-18. [PMID: 30455241 DOI: 10.1128/AAC.01363-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
507 Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021:ciab549. [PMID: 34164674 DOI: 10.1093/cid/ciab549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
508 Zhang X, Xu X, Wang J, Wang C, Yan Y, Wu A, Ren Y. Public-Health-Driven Microfluidic Technologies: From Separation to Detection. Micromachines (Basel) 2021;12:391. [PMID: 33918189 DOI: 10.3390/mi12040391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
509 Fordyce CB, Katz JN, Alviar CL, Arslanian-engoren C, Bohula EA, Geller BJ, Hollenberg SM, Jentzer JC, Sims DB, Washam JB, van Diepen S; On behalf of the American Heart Association Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Stroke Council. Prevention of Complications in the Cardiac Intensive Care Unit: A Scientific Statement From the American Heart Association. Circulation 2020;142. [DOI: 10.1161/cir.0000000000000909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
510 Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211020285. [PMID: 34104215 DOI: 10.1177/17562848211020285] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
511 Abhyankar MM, Ma JZ, Scully KW, Nafziger AJ, Frisbee AL, Saleh MM, Madden GR, Hays AR, Poulter M, Petri WA Jr. Immune Profiling To Predict Outcome of Clostridioides difficile Infection. mBio 2020;11:e00905-20. [PMID: 32457246 DOI: 10.1128/mBio.00905-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
512 Adams DJ, Barone JB, Nylund CM. Community-Associated Clostridioides difficile Infection in Children: A Review of Recent Literature. J Pediatric Infect Dis Soc 2021;10:S22-6. [PMID: 34791398 DOI: 10.1093/jpids/piab064] [Reference Citation Analysis]
513 Whyte C, Alhasani H, Caplan R, Tully AP. Impact of an external ventricular drain bundle and limited duration antibiotic prophylaxis on drain-related infections and antibiotic resistance. Clinical Neurology and Neurosurgery 2020;190:105641. [DOI: 10.1016/j.clineuro.2019.105641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
514 Houghton D. CE: Infection in Acute Care: Evidence for Practice. Am J Nurs 2019;119:24-32. [PMID: 31567249 DOI: 10.1097/01.NAJ.0000586160.03391.82] [Reference Citation Analysis]
515 Chen C, Chen Y, Liou J, Wu M; for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. From germ theory to germ therapy. Kaohsiung J Med Sci 2019;35:73-82. [DOI: 10.1002/kjm2.12011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
516 Ochfeld E, Balmert LC, Patel SJ, Muller WJ, Kociolek LK. Risk factors for Clostridioides (Clostridium) difficile infection following solid organ transplantation in children. Transpl Infect Dis 2019;21:e13149. [PMID: 31332916 DOI: 10.1111/tid.13149] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
517 Lambl BB, Altamimi S, Kaufman NE, Rein MS, Freeley M, Duram M, Krauss W, Kurowski J, O'Neill WE, Seeley P, Gagnon MJ, Phillips DE, Rubin MS. Leveraging Quality Improvement Science to Reduce C. difficile Infections in a Community Hospital. Jt Comm J Qual Patient Saf 2019;45:285-94. [PMID: 30527394 DOI: 10.1016/j.jcjq.2018.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
518 Long B, Koyfman A. Oncologic Emergencies: The Fever With Too Few Neutrophils. J Emerg Med 2019;57:689-700. [PMID: 31635928 DOI: 10.1016/j.jemermed.2019.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
519 Magro M, Rosenberg J, Epson E. Characterizing Clostridioides difficile infections and hospital exposures in California using surveillance and administrative data, 2014-2015. Infect Control Hosp Epidemiol 2021;42:292-7. [PMID: 32993820 DOI: 10.1017/ice.2020.447] [Reference Citation Analysis]
520 Yepez Guevara EA, Aitken SL, Olvera AV, Carlin L, Fernandes KE, Bhatti MM, Garey KW, Adachi J, Okhuysen PC. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clin Infect Dis 2021;72:e460-5. [PMID: 32803229 DOI: 10.1093/cid/ciaa1184] [Reference Citation Analysis]
521 Madden GR, Sifri CD. Reduced Clostridioides difficile Tests Among Solid Organ Transplant Recipients Through a Diagnostic Stewardship Bundled Intervention. Ann Transplant 2019;24:304-11. [PMID: 31133632 DOI: 10.12659/AOT.915168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
522 Harris TN, Szempruch KR, Dupuis RE, Serrano Rodriguez P, Toledo AH. Alemtuzumab in Renal Retransplantation - Transplant Outcomes and Associated Infections. Transplant Proc 2021:S0041-1345(21)00716-8. [PMID: 34774310 DOI: 10.1016/j.transproceed.2021.08.056] [Reference Citation Analysis]
523 McFarland LV, Ship N, Auclair J, Millette M. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. J Hosp Infect 2018;99:443-52. [PMID: 29702133 DOI: 10.1016/j.jhin.2018.04.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
524 Shah S, Ereshefsky B, Pontiggia L, Cawley M. Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection. Hosp Pharm 2019;54:294-9. [PMID: 31555004 DOI: 10.1177/0018578718787439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
525 Lanas-gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 2019;18:1043-53. [DOI: 10.1080/14740338.2019.1664470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
526 Vaughn VM, Greene MT, Ratz D, Fowler KE, Krein SL, Flanders SA, Dubberke ER, Saint S, Patel PK. Antibiotic stewardship teams and Clostridioides difficile practices in United States hospitals: A national survey in The Joint Commission antibiotic stewardship standard era. Infect Control Hosp Epidemiol 2020;41:143-8. [PMID: 31806059 DOI: 10.1017/ice.2019.313] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
527 Parshall DM, Sessa JE, Conn KM, Avery LM. The Impact of the Duration of Antibiotic Therapy in Patients With Community-Onset Pneumonia on Readmission Rates: A Retrospective Cohort Study. J Pharm Pract 2021;34:523-8. [PMID: 31645168 DOI: 10.1177/0897190019882260] [Reference Citation Analysis]
528 Worley J, Delaney ML, Cummins CK, DuBois A, Klompas M, Bry L. Genomic determination of relative risks for Clostridioides difficile infection from asymptomatic carriage in ICU patients. Clin Infect Dis 2020:ciaa894. [PMID: 32676661 DOI: 10.1093/cid/ciaa894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
529 Cheng Y, Fischer M. Clinical management of severe, fulminant, and refractory Clostridioides difficile infection. Expert Review of Anti-infective Therapy 2020;18:323-33. [DOI: 10.1080/14787210.2020.1730814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
530 Watson RL, Graber CJ. Lack of improvement in antimicrobial prescribing after a diagnosis of Clostridium difficile and impact on recurrence. Am J Infect Control 2018;46:1370-4. [PMID: 29779687 DOI: 10.1016/j.ajic.2018.04.213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
531 Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings 2020;95:758-69. [DOI: 10.1016/j.mayocp.2019.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
532 Mullish BH, Quraishi MN, Segal JP, Ianiro G, Iqbal TH. The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterol 2021;12:118-27. [PMID: 33613943 DOI: 10.1136/flgastro-2019-101376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
533 Sahra S, Abureesh M, Amarnath S, Alkhayyat M, Badran R, Jahangir A, Gumaste V. Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States. World J Hepatol 2021; 13(8): 926-938 [PMID: 34552699 DOI: 10.4254/wjh.v13.i8.926] [Reference Citation Analysis]
534 Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC, Lang K, Nelson WW. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 2021;9:2050312120986733. [PMID: 33505698 DOI: 10.1177/2050312120986733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
535 Gargiullo L, Del Chierico F, D'Argenio P, Putignani L. Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives. Front Microbiol 2019;10:1704. [PMID: 31402904 DOI: 10.3389/fmicb.2019.01704] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
536 Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant 2019;19:501-11. [PMID: 30085388 DOI: 10.1111/ajt.15058] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 12.8] [Reference Citation Analysis]
537 Takamatsu A, Yao K, Murakami S, Tagashira Y, Hasegawa S, Honda H. Barriers to Adherence to Antimicrobial Stewardship Postprescription Review and Feedback For Broad-Spectrum Antimicrobial Agents: A Nested Case-Control Study. Open Forum Infect Dis 2020;7:ofaa298. [PMID: 32832576 DOI: 10.1093/ofid/ofaa298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
538 Tomkovich S, Taylor A, King J, Colovas J, Bishop L, McBride K, Royzenblat S, Lesniak NA, Bergin IL, Schloss PD. An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance. mSphere 2021;6:e0062921. [PMID: 34585964 DOI: 10.1128/mSphere.00629-21] [Reference Citation Analysis]
539 Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm EJ. Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS One 2019;14:e0222881. [PMID: 31600222 DOI: 10.1371/journal.pone.0222881] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
540 Khanna S. Defending against a difficult clostridioides with a vaccine. Lancet Infect Dis 2021;21:157-8. [PMID: 32946837 DOI: 10.1016/S1473-3099(20)30356-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
541 Marinescu AR, Lăzureanu V, Laza R, Musta V, Nicolescu N, Cuț TG, Dehelean C, Oancea C, Licker M. Association between ribotype and clinical form of enterocolitis with C. difficile in Western Romania: A 2-year study. Exp Ther Med 2022;23:22. [PMID: 34815774 DOI: 10.3892/etm.2021.10944] [Reference Citation Analysis]
542 Agarwal A, Maheshwari A, Verma S, Arrup D, Phillips L, Vinayek R, Nair P, Hagan M, Dutta S. Superiority of Higher-Volume Fresh Feces Compared to Lower-Volume Frozen Feces in Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Colitis. Dig Dis Sci 2021;66:2000-4. [PMID: 32656604 DOI: 10.1007/s10620-020-06459-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
543 Carlson TJ, Endres BT, Bassères E, Gonzales-Luna AJ, Garey KW. Ridinilazole for the treatment of Clostridioides difficile infection. Expert Opin Investig Drugs 2019;28:303-10. [PMID: 30767587 DOI: 10.1080/13543784.2019.1582640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
544 Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, McDonald LC; Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med 2020;382:1320-30. [PMID: 32242357 DOI: 10.1056/NEJMoa1910215] [Cited by in Crossref: 132] [Cited by in F6Publishing: 65] [Article Influence: 66.0] [Reference Citation Analysis]
545 Lam SW, Bass SN. Advancing Infectious Diseases Diagnostic Testing and Applications to Antimicrobial Therapy in the ICU. J Pharm Pract 2019;32:327-38. [PMID: 30808257 DOI: 10.1177/0897190019831162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
546 Esme M, Topeli A, Yavuz BB, Akova M. Infections in the Elderly Critically-Ill Patients. Front Med (Lausanne) 2019;6:118. [PMID: 31275937 DOI: 10.3389/fmed.2019.00118] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
547 Attaar A, Wei J, Brunetti L. Evaluating Adherence to Guideline-Directed C Difficile Infection Management Pre- and Postimplementation of an Electronic Order Set. Journal of Pharmacy Practice 2021;34:721-6. [DOI: 10.1177/0897190020903854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
548 Martinez-Gili L, McDonald JAK, Liu Z, Kao D, Allegretti JR, Monaghan TM, Barker GF, Miguéns Blanco J, Williams HRT, Holmes E, Thursz MR, Marchesi JR, Mullish BH. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes 2020;12:1810531. [PMID: 32893721 DOI: 10.1080/19490976.2020.1810531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
549 Willis DN, Huang FS, Elward AM, Wu N, Magnusen B, Dubberke ER, Hayashi RJ. Clostridioides difficile Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes. J Pediatric Infect Dis Soc 2021;10:302-8. [PMID: 32766672 DOI: 10.1093/jpids/piaa090] [Reference Citation Analysis]
550 Lodise TP, Izmailyan S, Olesky M, Lawrence K. An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed? Open Forum Infect Dis 2020;7:ofaa237. [PMID: 32676511 DOI: 10.1093/ofid/ofaa237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Tantranont N, Hebert S, Truong LD. Vancomycin Nephrotoxicity Causing Renal Transplant Acute Kidney Injury. Transplant Proc 2021:S0041-1345(21)00730-2. [PMID: 34728076 DOI: 10.1016/j.transproceed.2021.09.033] [Reference Citation Analysis]
552 AlQahtani H, Baloch S, Tabb D. Treatment of Recurrent Clostridium difficile Infection in an Immunocompromised Patient with Severe Neutropenia Not Responding to Standard Therapy. Case Rep Infect Dis 2020;2020:3089023. [PMID: 32158569 DOI: 10.1155/2020/3089023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
553 Kara A, Tahir M, Snyderman W, Brinkman A, Fadel W, Dbeibo L. Why do clinicians order inappropriate Clostridium difficile testing? An exploratory study. Am J Infect Control 2019;47:285-9. [PMID: 30392996 DOI: 10.1016/j.ajic.2018.08.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
554 Manea E, Jipa R, Milea A, Roman A, Neagu G, Hristea A. Healthcare-associated Clostridioides difficile infection during the COVID-19 pandemic in a tertiary care hospital in Romania. Rom J Intern Med 2021. [PMID: 34053203 DOI: 10.2478/rjim-2021-0020] [Reference Citation Analysis]
555 Ma KGL, Lertpiriyapong K, Piersigilli A, Dobtsis I, Wipf JRK, Littmann ER, Leiner I, Pamer EG, Ricart Arbona RJ, Lipman NS. Outbreaks of Typhlocolitis Caused by Hypervirulent Group ST1 Clostridioides difficile in Highly Immunocompromised Strains of Mice. Comp Med 2020;70:277-90. [PMID: 32404234 DOI: 10.30802/AALAS-CM-19-000109] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
556 Leslie JL, Jenior ML, Vendrov KC, Standke AK, Barron MR, O'Brien TJ, Unverdorben L, Thaprawat P, Bergin IL, Schloss PD, Young VB. Protection from Lethal Clostridioides difficile Infection via Intraspecies Competition for Cogerminant. mBio 2021;12:e00522-21. [PMID: 33785619 DOI: 10.1128/mBio.00522-21] [Reference Citation Analysis]
557 Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232 [PMID: 34876784 DOI: 10.3748/wjg.v27.i42.7210] [Reference Citation Analysis]
558 Olesen SW, Gerardin Y. Re-Evaluating the Evidence for Faecal Microbiota Transplantation ‘Super-Donors’ in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2021;15:453-61. [DOI: 10.1093/ecco-jcc/jjaa170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
559 Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes 2020;4:14. [PMID: 32076853 DOI: 10.1186/s41687-020-0179-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
560 Krishna A, Chopra T. Prevention of Infection due to Clostridium (Clostridioides) difficile. Infect Dis Clin North Am 2021;35:995-1011. [PMID: 34752229 DOI: 10.1016/j.idc.2021.07.009] [Reference Citation Analysis]
561 Lam AY, Gutin LS, Nguyen Y, Velayos FS. Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients. Dig Dis Sci 2020;65:3111-5. [PMID: 32749638 DOI: 10.1007/s10620-020-06521-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
562 Amjad W, Qureshi W, Malik A, Singh R, Jafri SM. The outcomes of Clostridioides difficile infection in inpatient liver transplant population. Transpl Infect Dis 2021;:e13750. [PMID: 34695277 DOI: 10.1111/tid.13750] [Reference Citation Analysis]
563 Wei HS. Bacterial diarrhea in hospitalized children: Pathogen distribution and drug resistance. Shijie Huaren Xiaohua Zazhi 2018; 26(11): 680-686 [DOI: 10.11569/wcjd.v26.i11.680] [Reference Citation Analysis]
564 Shin JH, Hays RA, Warren CA. Hospitalized Older Patients with Clostridioides difficile Infection Refractory to Conventional Antibiotic Therapy Benefit from Fecal Microbiota Transplant. Adv Geriatr Med Res 2021;3:e210012. [PMID: 34263258 DOI: 10.20900/agmr20210012] [Reference Citation Analysis]
565 Ossorio PN, Zhou Y. FMT and Microbial Medical Products: Generating High-Quality Evidence through Good Governance. J Law Med Ethics 2019;47:505-23. [DOI: 10.1177/1073110519897727] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
566 Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;67:1920-1941. [PMID: 30154172 DOI: 10.1136/gutjnl-2018-316818] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 31.5] [Reference Citation Analysis]
567 Szymczak JE, Muller BM, Shakamuri NS, Hamilton KW, Gerber JS, Laguio-Vila M, Dumyati GK, Fridkin SK, Guh AY, Reddy SC, Lautenbach E; CDC Prevention Epicenters Program. Prescriber perceptions of fluoroquinolones, extended-spectrum cephalosporins, and Clostridioides difficile infection. Infect Control Hosp Epidemiol 2020;41:914-20. [PMID: 32468967 DOI: 10.1017/ice.2020.183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
568 Lee J, Joo H, Maskery BA, Alpern JD, Park C, Weinberg M, Stauffer WM. Increases in Anti-infective Drug Prices, Subsequent Prescribing, and Outpatient Costs. JAMA Netw Open 2021;4:e2113963. [PMID: 34143194 DOI: 10.1001/jamanetworkopen.2021.13963] [Reference Citation Analysis]
569 Jachowicz E, Różańska A, Pobiega M, Topolski M, Wójkowska-Mach J. Consumption of Antibiotics and Epidemiology of Clostridioides difficile in the European Union in 2016-Opportunity for Practical Application of Aggregate ECDC Data. Antibiotics (Basel) 2020;9:E127. [PMID: 32204381 DOI: 10.3390/antibiotics9030127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
570 Patel H, Makker J, Vakde T, Shaikh D, Badipatla K, Dunne J, Mantri N, Nayudu SK, Glandt M, Balar B, Chilimuri S. Nonsteroidal Anti-Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with Clostridium difficile Infection. Clin Exp Gastroenterol 2019;12:449-56. [PMID: 31849510 DOI: 10.2147/CEG.S223886] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
571 Khanna S, Tande A, Rubin DT, Khoruts A, Kahn SA, Pardi DS. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc 2021;96:1418-25. [PMID: 34088413 DOI: 10.1016/j.mayocp.2021.04.005] [Reference Citation Analysis]
572 Stalder T, Kapel N, Diaz S, Grenouillet F, Koch S, Limat S, Daval F, Vuitton L, Nerich V. A systematic review of economic evaluation in fecal microbiota transplantation. Infect Control Hosp Epidemiol 2020;41:458-66. [DOI: 10.1017/ice.2019.371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
573 Madden GR, Enfield KB, Sifri CD. Patient Outcomes With Prevented vs Negative Clostridioides difficile Tests Using a Computerized Clinical Decision Support Tool. Open Forum Infect Dis 2020;7:ofaa094. [PMID: 32328506 DOI: 10.1093/ofid/ofaa094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
574 Essrani R, Saturno D, Mehershahi S, Essrani RK, Hossain MR, Ravi SJK, Berger A, Mehmood A. The Impact of Appendectomy in Clostridium difficile Infection and Length of Hospital Stay. Cureus. 2020;12:e10342. [PMID: 33062466 DOI: 10.7759/cureus.10342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
575 Al-Bakri AG, Akour AA, Al-Delaimy WK. Knowledge, attitudes, ethical and social perspectives towards fecal microbiota transplantation (FMT) among Jordanian healthcare providers. BMC Med Ethics 2021;22:19. [PMID: 33639935 DOI: 10.1186/s12910-021-00587-6] [Reference Citation Analysis]
576 Khurana S, Kahl A, Yu K, DuPont AW. Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Fac Rev 2020;9:13. [PMID: 33659945 DOI: 10.12703/b/9-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
577 Brauer M, Herrmann J, Zühlke D, Müller R, Riedel K, Sievers S. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis. Gut Pathog 2022;14:4. [PMID: 34991700 DOI: 10.1186/s13099-021-00475-9] [Reference Citation Analysis]
578 Lin Z, Iqbal Z, Ortiz JF, Khan SA, Jahan N. Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infection: Is it Superior to Other Conventional Methods? Cureus 2020;12:e9653. [PMID: 32923252 DOI: 10.7759/cureus.9653] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
579 Chong PP, Koh AY. The gut microbiota in transplant patients. Blood Rev 2020;39:100614. [PMID: 31492463 DOI: 10.1016/j.blre.2019.100614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
580 Abughanimeh O, Qasrawi A, Kaddourah O, Al Momani L, Abu Ghanimeh M. Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment. Hosp Pract (1995) 2018;46:266-77. [PMID: 30296190 DOI: 10.1080/21548331.2018.1533673] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
581 Yamamura Y, Ohhira T, Ishii S, Nakatani K, Nagata K. Fulminant Clostridioides difficile infection in an infant. Pediatr Int 2020;62:1401-3. [PMID: 33201533 DOI: 10.1111/ped.14352] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
582 Romyasamit C, Thatrimontrichai A, Aroonkesorn A, Chanket W, Ingviya N, Saengsuwan P, Singkhamanan K. Enterococcus faecalis Isolated From Infant Feces Inhibits Toxigenic Clostridioides (Clostridium) difficile. Front Pediatr 2020;8:572633. [PMID: 33102409 DOI: 10.3389/fped.2020.572633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
583 Misawa K, Iketani O, Enoki Y, Taguchi K, Uno S, Uwamino Y, Hasegawa N, Matsumoto K. Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile infection. J Infect Chemother 2021;27:1407-12. [PMID: 34023223 DOI: 10.1016/j.jiac.2021.05.010] [Reference Citation Analysis]
584 Groves HE, Allen UD. Winning with poo? Fecal microbiome transplantation as an emerging strategy for the management of recurrent Clostridioides difficile infection in children. Pediatr Transplant 2020;24:e13651. [PMID: 31975529 DOI: 10.1111/petr.13651] [Reference Citation Analysis]
585 Turner NA, Saullo JL, Polage CR. Healthcare associated diarrhea, not Clostridioides difficile. Curr Opin Infect Dis 2020;33:319-26. [PMID: 32657969 DOI: 10.1097/QCO.0000000000000653] [Reference Citation Analysis]
586 Boly FJ, Reske KA, Kwon JH. The Role of Diagnostic Stewardship in Clostridioides difficile Testing: Challenges and Opportunities. Curr Infect Dis Rep 2020;22:7. [PMID: 33762897 DOI: 10.1007/s11908-020-0715-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
587 Mora Pinzon MC, Buie R, Liou J, Shirley DK, Evans CT, Ramanathan S, Poggensee L, Safdar N. Outcomes of Community and Healthcare-onset Clostridium difficile Infections. Clinical Infectious Diseases 2019;68:1343-50. [DOI: 10.1093/cid/ciy715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
588 Lin K, Zahlanie Y, Ortwine JK, Mang NS, Wei W, Brown LS, Prokesch BC. Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative. Open Forum Infect Dis 2020;7:ofaa182. [PMID: 32548204 DOI: 10.1093/ofid/ofaa182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
589 Skinner AM, Scardina T, Kociolek LK. Fidaxomicin for the treatment of Clostridioides difficile in children. Future Microbiol 2020;15:967-79. [PMID: 32715754 DOI: 10.2217/fmb-2020-0104] [Reference Citation Analysis]
590 Wilsey HA, Burgess DR, Burgess DS. Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2020;64:e00360-20. [PMID: 32366709 DOI: 10.1128/AAC.00360-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
591 Yang J, Yang H. Non-antibiotic therapy for Clostridioides difficile infection: a review. Crit Rev Clin Lab Sci 2019;56:493-509. [PMID: 31411909 DOI: 10.1080/10408363.2019.1648377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
592 Dalton KR, Rock C, Carroll KC, Davis MF. One Health in hospitals: how understanding the dynamics of people, animals, and the hospital built-environment can be used to better inform interventions for antimicrobial-resistant gram-positive infections. Antimicrob Resist Infect Control 2020;9:78. [PMID: 32487220 DOI: 10.1186/s13756-020-00737-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
593 Vedala K, Sobash P, Shah P, Kamoga GR. Does Fecal Microbiota Transplant Have a Role in Treating Recurrent Clostridioides difficile Infection in Rural Hospitals? Front Public Health 2021;9:670941. [PMID: 34178927 DOI: 10.3389/fpubh.2021.670941] [Reference Citation Analysis]
594 Berkefeld A, Berger FK, Gärtner BC, Wantia N, Prinzing A, Laugwitz KL, Busch DH, Rothe K. Clostridioides (Clostridium) difficile Pacemaker Infection. Open Forum Infect Dis 2020;7:ofaa487. [PMID: 33324719 DOI: 10.1093/ofid/ofaa487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
595 Paschos P, Ioakim K, Malandris K, Koukoufiki A, Nayfeh T, Akriviadis E, Tsapas A, Bekiari E. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Anaerobe 2021;71:102441. [PMID: 34454094 DOI: 10.1016/j.anaerobe.2021.102441] [Reference Citation Analysis]
596 Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 2020;52:12-20. [PMID: 31801387 DOI: 10.1080/07853890.2019.1701703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
597 Volkmann ER, Hoffmann-Vold AM. Gastrointestinal tract microbiota modifications in systemic sclerosis. Eur J Rheumatol 2020;7:S228-36. [PMID: 31922474 DOI: 10.5152/eurjrheum.2019.19103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
598 Lodise T, Rodriguez M, Chitra S, Wright K, Patel N. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective. Antibiotics (Basel) 2021;10:1195. [PMID: 34680776 DOI: 10.3390/antibiotics10101195] [Reference Citation Analysis]
599 Davidovics ZH, Michail S, Nicholson MR, Kociolek LK, Pai N, Hansen R, Schwerd T, Maspons A, Shamir R, Szajewska H, Thapar N, de Meij T, Mosca A, Vandenplas Y, Kahn SA, Kellermayer R; FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2019;68:130-43. [PMID: 30540704 DOI: 10.1097/MPG.0000000000002205] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 21.5] [Reference Citation Analysis]
600 Cheng YW, Phelps E, Nemes S, Rogers N, Sagi S, Bohm M, El-Halabi M, Allegretti JR, Kassam Z, Xu H, Fischer M. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. Clin Gastroenterol Hepatol 2020;18:2234-2243.e1. [PMID: 31923639 DOI: 10.1016/j.cgh.2019.12.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
601 Vent-Schmidt J, Attara GP, Lisko D, Steiner TS. Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey. Patient Prefer Adherence 2020;14:33-43. [PMID: 32021115 DOI: 10.2147/PPA.S229539] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
602 Lee J, Hung Y, Tsai B, Tsai P, Ko W. Severe Clostridium difficile infections in intensive care units: Diverse clinical presentations. Journal of Microbiology, Immunology and Infection 2020. [DOI: 10.1016/j.jmii.2020.07.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
603 Chen Y, Xiang Q, Liu L. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients. J Int Med Res 2021;49:3000605211019661. [PMID: 34057835 DOI: 10.1177/03000605211019661] [Reference Citation Analysis]
604 Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol 2021;116:647-56. [PMID: 33982930 DOI: 10.14309/ajg.0000000000001075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
605 Multani A, Moayedi Y, Puing A, Henricksen E, Garvert DW, Gomez CA, Tremblay-Gravel M, Bunce PE, Luikart H, Ross HJ, Khush KK, Montoya JG, Teuteberg JJ. Recent Trends of Infectious Complications Following Heart Transplantation. Transplantation 2020;104:e284-94. [PMID: 32413012 DOI: 10.1097/TP.0000000000003307] [Reference Citation Analysis]
606 Eberly MD, Susi A, Adams DJ, Love CS, Nylund CM. Epidemiology and Outcomes of Patients With Healthcare Facility-Onset Clostridioides difficile Infection. Mil Med 2021:usab116. [PMID: 33772561 DOI: 10.1093/milmed/usab116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
607 Balaji AB, Sichel JS, Kociolek LK. Lack of false-positive results for Clostridioides difficile toxins A and B using two commercial enzyme immunoassays in pediatric patients. Infect Control Hosp Epidemiol 2019;40:825-6. [PMID: 31032759 DOI: 10.1017/ice.2019.104] [Reference Citation Analysis]
608 Viel-Thériault I, Bettolli M, Toye B, Harrison MA, Le Saux N. Contemporary Microbiology and Antimicrobial Treatment of Complicated Appendicitis: The Value of a Short-term Study. Pediatr Infect Dis J 2019;38:e290-4. [PMID: 31365479 DOI: 10.1097/INF.0000000000002420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
609 Asai N, Sakanashi D, Suematsu H, Kato H, Shiota A, Hagihara M, Koizumi Y, Yamagishi Y, Mikamo H. Observational study in a single institute in Japan: How many community-onset pneumonia patients would have Clostridioides difficile infections after treatment? J Infect Chemother 2020;26:1104-6. [PMID: 32713744 DOI: 10.1016/j.jiac.2020.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
610 Atteberry P, Biederman B, Jesudian A, Lucero C, Brown RS Jr, Verna E, Sundaram V, Fortune B, Rosenblatt R. Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection. J Gastroenterol Hepatol 2021. [PMID: 34293211 DOI: 10.1111/jgh.15633] [Reference Citation Analysis]
611 Pal R, Dai M, Seleem MN. High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile in vitro. Sci Rep 2021;11:10913. [PMID: 34035338 DOI: 10.1038/s41598-021-90314-3] [Reference Citation Analysis]
612 Lin TC, Hung YP, Ko WC, Ruan JW. Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation. J Microbiol Immunol Infect 2019;52:841-50. [PMID: 31607571 DOI: 10.1016/j.jmii.2019.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
613 Wang C, Liu M, Wang Z, Li S, Deng Y, He N. Point-of-care diagnostics for infectious diseases: From methods to devices. Nano Today 2021;37:101092. [PMID: 33584847 DOI: 10.1016/j.nantod.2021.101092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
614 Sattler MM, Crews JD. Challenges in the Diagnosis and Management of Recurrent and Severe Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc 2021;10:S27-33. [PMID: 34791399 DOI: 10.1093/jpids/piab079] [Reference Citation Analysis]
615 Austin K, Sweet M, Likar E, LaSala PR, Murray A, Wen S, Ross KG, Kanate AS, Veltri L, Matuga R, Cumpston A. Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients. Transpl Infect Dis 2020;22:e13438. [PMID: 32767807 DOI: 10.1111/tid.13438] [Reference Citation Analysis]
616 Martínez-Meléndez A, Tijerina-Rodríguez L, Collins N, Baines SD, Morfin-Otero R, Camacho-Ortíz A, Villarreal-Treviño L, Garza-González E. Diversity of Circulating Clostridioides difficile Ribotypes in Mexico and Susceptibility to Fidaxomicin, Vancomycin, and Metronidazole. Microb Drug Resist 2021. [PMID: 34037477 DOI: 10.1089/mdr.2020.0583] [Reference Citation Analysis]
617 Rao K, Malani PN. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020. JAMA 2020;323:1403-4. [PMID: 32150234 DOI: 10.1001/jama.2019.3849] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
618 Tan GSE, Tay HL, Tan SH, Lee TH, Ng TM, Lye DC. Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship. Adv Ther 2020;37:4054-67. [PMID: 32767183 DOI: 10.1007/s12325-020-01458-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
619 Wombwell E, Bransteitter B, Gillen LR. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic. Mycoses 2021;64:1521-6. [PMID: 34585799 DOI: 10.1111/myc.13375] [Reference Citation Analysis]
620 Han Z, Lapin B, Garey KW, Donskey CJ, Deshpande A. Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol 2021;:1-6. [PMID: 34615561 DOI: 10.1017/ice.2021.413] [Reference Citation Analysis]
621 Pham CD, Hua DT. Clostridium difficile appendicitis in an immunocompromised patient: a case report and review of the literature. J Med Case Rep 2021;15:2. [PMID: 33402156 DOI: 10.1186/s13256-020-02592-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
622 Calu V, Toma EA, Enciu O, Miron A. Clostridium difficile Infection and Colorectal Surgery: Is There Any Risk? Medicina (Kaunas) 2019;55:E683. [PMID: 31658780 DOI: 10.3390/medicina55100683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
623 Ruan W, Kellermayer R. Alternative Diagnoses in Pediatric Fecal Microbiota Transplant Referral Patients. J Pediatr Gastroenterol Nutr 2021;72:693-6. [PMID: 33534360 DOI: 10.1097/MPG.0000000000003060] [Reference Citation Analysis]
624 Carlson TJ, Gonzales-luna AJ. Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00730-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
625 Leal SM Jr, Popowitch EB, Levinson KJ, John TM, Lehman B, Rios MB, Gilligan PH, Miller MB. Quantitative Thresholds Enable Accurate Identification of Clostridium difficile Infection by the Luminex xTAG Gastrointestinal Pathogen Panel. J Clin Microbiol 2018;56:e01885-17. [PMID: 29643194 DOI: 10.1128/JCM.01885-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
626 Mashock MJ, Faron ML, Carroll KC, Dang C, Lewis S, Salimnia H, Lephart P, Loo VG, Schmitt BH, Young S, Buchan BW, Ledeboer NA. A Multicenter Study of the Revogene C. difficile System for Detection of the Toxin B Gene from Unformed Stool Specimens. J Clin Microbiol 2020;58:e01510-19. [PMID: 31776191 DOI: 10.1128/JCM.01510-19] [Reference Citation Analysis]
627 Sopena N, Freixas N, Bella F, Pérez J, Hornero A, Limon E, Gudiol F, Pujol M; VINCat Clostridioides difficile study group. Impact of a training program on the surveillance of Clostridioides difficile infection. Epidemiol Infect 2019;147:e231. [PMID: 31364565 DOI: 10.1017/S0950268819001080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
628 Shao X, AbdelKhalek A, Abutaleb NS, Velagapudi UK, Yoganathan S, Seleem MN, Talele TT. Chemical Space Exploration around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors. J Med Chem 2019;62:9772-91. [PMID: 31584822 DOI: 10.1021/acs.jmedchem.9b01198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
629 Núñez F P, Quera R, Bay C, Thomson P. Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. Gastroenterol Hepatol 2021:S0210-5705(21)00192-8. [PMID: 34118321 DOI: 10.1016/j.gastrohep.2021.05.009] [Reference Citation Analysis]
630 Goldstein EJC, Citron DM, Tyrrell KL, Leoncio E. In vitro stability of three oral vancomycin preparations stored at 2- 5 °C and ambient room temperature for up to 60 days against 100 Clostridioides (Clostridium) difficile and 51Staphylococcus aureus strains. Anaerobe 2018;52:83-5. [PMID: 29902515 DOI: 10.1016/j.anaerobe.2018.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
631 Adelman MW, Woodworth MH, Shaffer VO, Martin GS, Kraft CS. Critical Care Management of the Patient with Clostridioides difficile. Crit Care Med 2021;49:127-39. [PMID: 33156122 DOI: 10.1097/CCM.0000000000004739] [Reference Citation Analysis]
632 Okada Y, Yagihara Y, Wakabayashi Y, Igawa G, Saito R, Higurashi Y, Ikeda M, Tatsuno K, Okugawa S, Moriya K. Epidemiology and virulence-associated genes of Clostridioides difficile isolates and factors associated with toxin EIA results at a university hospital in Japan. Access Microbiol 2020;2:acmi000086. [PMID: 34568752 DOI: 10.1099/acmi.0.000086] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
633 McLean K, Balada-Llasat JM, Waalkes A, Pancholi P, Salipante SJ. Whole-genome sequencing of clinical Clostridioides difficile isolates reveals molecular epidemiology and discrepancies with conventional laboratory diagnostic testing. J Hosp Infect 2021;108:64-71. [PMID: 33227298 DOI: 10.1016/j.jhin.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
634 Hebert C, Root ED. Repurposing Geographic Information Systems for Routine Hospital Infection Control. Adv Health Care Manag 2019;18. [PMID: 32077658 DOI: 10.1108/S1474-823120190000018003] [Reference Citation Analysis]
635 Wilcox MH, Rahav G, Dubberke ER, Gabryelski L, Davies K, Berry C, Eves K, Ellison MC, Guris D, Dorr MB. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. Open Forum Infect Dis 2019;6:ofz293. [PMID: 31375837 DOI: 10.1093/ofid/ofz293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
636 Chung HS, Park JS, Shin BM. Laboratory Diagnosis of Clostridium difficile Infection in Korea: The First National Survey. Ann Lab Med 2019;39:317-21. [PMID: 30623624 DOI: 10.3343/alm.2019.39.3.317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
637 Luo Y, Grinspan LT, Fu Y, Adams-Sommer V, Willey DK, Patel G, Grinspan AM. Hospital-onset Clostridioides difficile infections during the COVID-19 pandemic. Infect Control Hosp Epidemiol 2020;:1-2. [PMID: 32962772 DOI: 10.1017/ice.2020.1223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
638 Radhakrishnan P, Vishwanath M, Shemin D, Monteiro JFG, D'Agata EMC. Clostridioides difficile Infection Among Patients Requiring Maintenance Hemodialysis. Kidney Med 2021;3:467-70. [PMID: 34136796 DOI: 10.1016/j.xkme.2021.02.005] [Reference Citation Analysis]
639 Jones JA, Prior AM, Marreddy RKR, Wahrmund RD, Hurdle JG, Sun D, Hevener KE. Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity. ACS Chem Biol 2019;14:1528-35. [PMID: 31184849 DOI: 10.1021/acschembio.9b00293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
640 Muhammad A, Madhav D, Rawish F, Viveksandeep TC, Albert E, Mollie J, Prateek S. Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis. CCP 2019;14:166-74. [DOI: 10.2174/1574884714666190328162637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
641 Principi N, Gnocchi M, Gagliardi M, Argentiero A, Neglia C, Esposito S. Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem. Microorganisms 2020;8:E1640. [PMID: 33114040 DOI: 10.3390/microorganisms8111640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
642 Cheknis A, Devaris D, Chesnel L, Dale SE, Nary J, Sambol SP, Citron DM, Goering RV, Johnson S. Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities. J Antimicrob Chemother 2020;75:3120-5. [PMID: 32747931 DOI: 10.1093/jac/dkaa297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
643 Badilla-Lobo A, Rodríguez C. Microbiological features, epidemiology, and clinical presentation of Clostridioidesdifficile strains from MLST Clade 2: A narrative review. Anaerobe 2021;69:102355. [PMID: 33711422 DOI: 10.1016/j.anaerobe.2021.102355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
644 Nakaie K, Yamada K, Kuwabara G, Imoto W, Yamairi K, Shibata W, Oshima K, Niki M, Sakurai N, Nonose Y, Okada Y, Fujita A, Kaneko Y, Kakeya H. Three-year epidemiological analysis of Clostridioides difficile infection and the value of hospital-infection control measures in a tertiary-care teaching hospital in Japan using PCR-based open-reading frame typing. J Infect Chemother 2021;27:179-84. [PMID: 32950394 DOI: 10.1016/j.jiac.2020.08.020] [Reference Citation Analysis]
645 Alonso CD, Papamichael K, Sprague R, Barrett C, Gonzales-Luna AJ, Daugherty K, Garey KW, Villafuerte-Gálvez J, Xu H, Lin Q, Wang L, Chen X, Pollock NR, Kelly CP. Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection. Open Forum Infect Dis 2021;8:ofab286. [PMID: 34258317 DOI: 10.1093/ofid/ofab286] [Reference Citation Analysis]
646 Brechmann T, Günther K, Neid M, Tannapfel A, Schmiegel W. Phenotype of histologically suspected drug-induced colitis; results of a comparative, retrospective cohort study. Scand J Gastroenterol 2019;54:855-62. [PMID: 31215277 DOI: 10.1080/00365521.2019.1630674] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
647 Martin LT, Vincent S, Gillian S, Moore K, Ratermann D, Droege CA. Pharmacologic Approach to Management of Clostridium difficile Infection. Crit Care Nurs Q 2019;42:2-11. [PMID: 30507659 DOI: 10.1097/CNQ.0000000000000232] [Reference Citation Analysis]
648 Juretschko S, Manji R, Khare R, Das S, Dunbar S. Performance Evaluation of the Luminex Aries C. difficile Assay in Comparison to Two Other Molecular Assays within a Multihospital Health Care Center. J Clin Microbiol 2019;57:e01092-19. [PMID: 31413082 DOI: 10.1128/JCM.01092-19] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
649 Medaglia AA, Buffa S, Gioè C, Bonura S, Rubino R, Iaria C, Colomba C, Cascio A. An emergent infectious disease: Clostridioides difficile infection hospitalizations, 10-year trend in Sicily. Infection 2021;49:1221-9. [PMID: 34495497 DOI: 10.1007/s15010-021-01683-w] [Reference Citation Analysis]
650 Legenza L, Barnett S, Rose W, Bianchini M, Safdar N, Coetzee R. Epidemiology and outcomes of Clostridium difficile infection among hospitalised patients: results of a multicentre retrospective study in South Africa. BMJ Glob Health 2018;3:e000889. [PMID: 30057799 DOI: 10.1136/bmjgh-2018-000889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
651 AbdelKhalek A, Mohammad H, Mayhoub AS, Seleem MN. Screening for potent and selective anticlostridial leads among FDA-approved drugs. J Antibiot (Tokyo) 2020;73:392-409. [PMID: 32132676 DOI: 10.1038/s41429-020-0288-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
652 Saha S, Kapoor S, Tariq R, Schuetz AN, Tosh PK, Pardi DS, Khanna S. Increasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis. Anaerobe 2019;58:35-46. [PMID: 31330183 DOI: 10.1016/j.anaerobe.2019.102072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
653 Karaoui WR, Rustam LBO, Bou Daher H, Rimmani HH, Rasheed SS, Matar GM, Mahfouz R, Araj GF, Zahreddine N, Kanj SS, Berger FK, Gärtner B, El Sabbagh R, Sharara AI. Incidence, outcome, and risk factors for recurrence of nosocomial Clostridioides difficile infection in adults: A prospective cohort study. J Infect Public Health 2020;13:485-90. [PMID: 31838001 DOI: 10.1016/j.jiph.2019.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
654 Schlaberg R, Barrett A, Edes K, Graves M, Paul L, Rychert J, Lopansri BK, Leung DT. Fecal Host Transcriptomics for Non-Invasive Human Mucosal Immune Profiling: Proof of Concept in Clostridium Difficile Infection. Pathog Immun 2018;3:164-80. [PMID: 30283823 DOI: 10.20411/pai.v3i2.250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
655 Khanna S. A defined microbiome therapeutic prevents recurrent Clostridioides difficile. Lancet Gastroenterol Hepatol 2021;6:255-6. [PMID: 33631103 DOI: 10.1016/S2468-1253(21)00011-X] [Reference Citation Analysis]
656 Khanna S. My Treatment Approach to Clostridioides difficile Infection. Mayo Clin Proc 2021;96:2192-204. [PMID: 34175104 DOI: 10.1016/j.mayocp.2021.03.033] [Reference Citation Analysis]
657 Yin J, Kociolek LK, Same RG, Hsu AJ, Amoah J, Tamma PD. Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections. Open Forum Infect Dis 2019;6:ofz492. [PMID: 31950069 DOI: 10.1093/ofid/ofz492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
658 Phanchana M, Phetruen T, Harnvoravongchai P, Raksat P, Ounjai P, Chankhamhaengdecha S, Janvilisri T. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Sci Rep 2020;10:6497. [PMID: 32300130 DOI: 10.1038/s41598-020-63199-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
659 Howard-Anderson JR, Sexton ME, Robichaux C, Wiley Z, Varkey JB, Suchindran S, Albrecht B, Ashley Jones K, Fridkin SK, Jacob JT. The impact of an electronic medical record nudge on reducing testing for hospital-onset Clostridioides difficile infection. Infect Control Hosp Epidemiol 2020;41:411-7. [PMID: 32036798 DOI: 10.1017/ice.2020.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
660 Utay NS, Monczor AN, Somasunderam A, Lupo S, Jiang ZD, Alexander AS, Finkelman M, Vigil KJ, Lake JE, Hanson B, DuPont HL, Arduino RC. Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV. Pathog Immun 2020;5:364-81. [PMID: 33501400 DOI: 10.20411/pai.v5i1.388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
661 Champredon D, Shoukat A, Moghadas SM. Effectiveness and cost-effectiveness of a Clostridium difficile vaccine candidate in a hospital setting. Vaccine 2020;38:2585-91. [PMID: 32014268 DOI: 10.1016/j.vaccine.2020.01.073] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
662 Carroll KC, Mizusawa M. Laboratory Tests for the Diagnosis of Clostridium difficile. Clin Colon Rectal Surg 2020;33:73-81. [PMID: 32104159 DOI: 10.1055/s-0039-3400476] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
663 Liang Y, He X, Wang T, Chen Y, Huang H, Tang W, Li Y. Massive Hydrothorax and Ascites as the Primary Manifestation of Infection With Clostridium difficile: A Case Report and Literature Review. Front Pediatr 2020;8:254. [PMID: 32509714 DOI: 10.3389/fped.2020.00254] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
664 Hammeken LH, Baunwall SMD, Hvas CL, Ehlers LH. Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review. Health Econ Rev 2021;11:3. [PMID: 33439367 DOI: 10.1186/s13561-021-00301-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
665 D'Agata EMC, Apata IW, Booth S, Boyce JM, Deaver K, Gualandi N, Neu A, Nguyen D, Novosad S, Palevsky PM, Rodgers D; Nephrologist Transforming Dialysis Safety Committee. Electronic address: ntds@asn-online.org. Suggestions for the prevention of Clostridioides difficile spread within outpatient hemodialysis facilities. Kidney Int 2021;99:1045-53. [PMID: 33667504 DOI: 10.1016/j.kint.2021.02.028] [Reference Citation Analysis]
666 Doll M, Marra AR, Apisarnthanarak A, Al-Maani AS, Abbas S, Rosenthal VD. Prevention of Clostridioides difficile in hospitals: A position paper of the International Society for Infectious Diseases. Int J Infect Dis 2021;102:188-95. [PMID: 33122100 DOI: 10.1016/j.ijid.2020.10.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
667 Baron SW, Ostrowsky BE, Nori P, Drory DY, Levi MH, Szymczak WA, Rinke ML, Southern WN. Screening of Clostridioides difficile carriers in an urban academic medical center: Understanding implications of disease. Infect Control Hosp Epidemiol 2020;41:149-53. [PMID: 31822302 DOI: 10.1017/ice.2019.309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
668 O’grady K, Knight DR, Riley TV. Antimicrobial resistance in Clostridioides difficile. Eur J Clin Microbiol Infect Dis. [DOI: 10.1007/s10096-021-04311-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
669 Anjewierden S, Han Z, Brown AM, Donskey CJ, Deshpande A. Risk factors for Clostridioides difficile colonization among hospitalized adults: A meta-analysis and systematic review. Infect Control Hosp Epidemiol 2021;42:565-72. [PMID: 33118886 DOI: 10.1017/ice.2020.1236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
670 Saha S, Yadav D, Pardi R, Patel R, Khanna S, Pardi D. Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211050443. [PMID: 34646361 DOI: 10.1177/17562848211050443] [Reference Citation Analysis]
671 Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in Treatment of Recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11:465-471. [PMID: 31236163 DOI: 10.14740/jocmr3854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
672 Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol 2021. [PMID: 34837014 DOI: 10.1038/s41579-021-00660-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Mi H, Bao R, Xiao Y, Cui Y, Sun W, Shen Y, Shi Q, Chen X, Lin J, Hu B, Gao X. Colonization of Toxigenic Clostridium difficile Among Intensive Care Unit Patients: A Multi-Centre Cross-Sectional Study. Front Cell Infect Microbiol 2020;10:12. [PMID: 32083021 DOI: 10.3389/fcimb.2020.00012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
674 De Wolfe TJ, Kates AE, Barko L, Darien BJ, Safdar N. Modified Mouse Model of Clostridioides difficile Infection as a Platform for Probiotic Efficacy Studies. Antimicrob Agents Chemother 2019;63:e00111-19. [PMID: 30988143 DOI: 10.1128/AAC.00111-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
675 Cogen JD, Kahl BC, Maples H, McColley SA, Roberts JA, Winthrop KL, Morris AM, Holmes A, Flume PA, VanDevanter DR, Waters V, Muhlebach MS, Elborn JS, Saiman L, Bell SC; Antimicrobial Resistance International Working Group in Cystic Fibrosis. Finding the relevance of antimicrobial stewardship for cystic fibrosis. J Cyst Fibros 2020;19:511-20. [PMID: 32122785 DOI: 10.1016/j.jcf.2020.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
676 Tixier EN, Verheyen E, Luo Y, Grinspan LT, Du CH, Ungaro RC, Walsh S, Grinspan AM. Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile. Dig Dis Sci 2021. [PMID: 33748913 DOI: 10.1007/s10620-021-06908-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
677 Weinstein N, Garten B, Vainer J, Minaya D, Czaja K. Managing the Microbiome: How the Gut Influences Development and Disease. Nutrients 2020;13:E74. [PMID: 33383647 DOI: 10.3390/nu13010074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
678 Nace DA, Fridkin SK. Are Antibiograms Ready for Prime Time in the Nursing Home? Journal of the American Medical Directors Association 2020;21:8-11. [DOI: 10.1016/j.jamda.2019.11.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
679 Su F, Luo Y, Yu J, Shi J, Zhao Y, Yan M, Huang H, Tan Y. Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review. Eur J Med Res 2021;26:37. [PMID: 33910622 DOI: 10.1186/s40001-021-00508-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
680 Ochoa-Hein E, Rajme-López S, Rodríguez-Aldama JC, Huertas-Jiménez MA, Chávez-Ríos AR, de Paz-García R, Haro-Osnaya A, González-Colín KK, González-González R, González-Lara MF, Ponce-de-León A, Galindo-Fraga A. Substantial reduction of healthcare facility-onset Clostridioides difficile infection (HO-CDI) rates after conversion of a hospital for exclusive treatment of COVID-19 patients. Am J Infect Control 2021;49:966-8. [PMID: 33352250 DOI: 10.1016/j.ajic.2020.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
681 Piatek J, Krauss H, Ciechelska-Rybarczyk A, Bernatek M, Wojtyla-Buciora P, Sommermeyer H. In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters. Int J Environ Res Public Health 2020;17:E3332. [PMID: 32403297 DOI: 10.3390/ijerph17093332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
682 Arroyo-Mercado F, Khudyakov A, Chawla GS, Cantres-Fonseca O, McFarlane IM. Red Man Syndrome with Oral Vancomycin: A Case Report. Am J Med Case Rep 2019;7:16-7. [PMID: 31123702 DOI: 10.12691/ajmcr-7-1-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
683 Sabus A, Merrow M, Heiden A, Boster J, Koo J, Franklin ARK. Fecal Microbiota Transplantation for Treatment of Severe Clostridioides difficile Colitis in a Pediatric Patient With Non-Hodgkin Lymphoma. J Pediatr Hematol Oncol 2021;43:e897-9. [PMID: 33273413 DOI: 10.1097/MPH.0000000000002023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
684 Ashraf MF, Tageldin O, Nassar Y, Batool A. Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection: A Four-Year Single-Center Retrospective Review. Gastroenterology Res 2021;14:237-43. [PMID: 34527093 DOI: 10.14740/gr1436] [Reference Citation Analysis]
685 Gentry CA, Campbell DL, Williams RJ. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study. Int J Antimicrob Agents 2021;57:106282. [PMID: 33465458 DOI: 10.1016/j.ijantimicag.2021.106282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]